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Background.  Emergence of HIV-specific CD8 T cells during acute HIV infection is associated 
with significant reduction in HIV viral loads in plasma, restoration of CD4 T cell numbers in 
blood and resolution of the clinical symptoms associated with acute disease.  Recent studies have 
shown that HIV-specific CD8 T cells that recognize conserved proteins such as Gag during both 
acute and chronic HIV infection are associated with better control of HIV replication.  
Unraveling the events during early infection that are associated with initial control of HIV 
replication and viral load may provide clues to the useful targets for development of efficacious 
therapy.  The aim of this study was to compare the magnitude and breadth of HIV-specific T cell 
responses to HIV Gag and Nef mounted during acute HIV infection with those that emerged 
during chronic infection and to investigate the association of these responses with subsequent 
HIV disease progression (CD4 counts and plasma viral loads).  
Method.  Seven acutely HIV-infected women were enrolled into the acute HIV infection study at 
a mean of 21 days post-infection in collaboration with the Desmond Tutu HIV Foundation.  In 
addition, nine long term non-progressors (LTNPs) who had been HIV infected for more than five 
years and maintained CD4 counts >350 in the absence of HAART were included for comparison.  
In both acute and LTNPs, the magnitude and breadth of IFN-γ T cell responses to HIV-1 subtype 
C Du422 Gag and/or consensus Nef overlapping peptides were assessed longitudinally by IFN-g 
ELISPOT.  CD4 T cell counts and HIV-1 RNA loads in blood were measured at every visit. 
Results.  In women who were acutely infected with HIV, blood CD4 T cell counts were inversely 
associated with plasma HIV-1 RNA loads.  In contrast, no correlation was found between CD4 T 
cell counts and plasma viral loads in LTNPs.  The breadth of HIV-specific responses to both Gag 
and Nef peptide pools was narrow and responses were lower in magnitude during acute HIV 
infection compared to responses detected in the same individuals during chronic HIV infection.  
More women had detectable HIV Gag responses during acute infection than Nef although 
responses to Nef were generally higher in magnitude.  IFN-g responses in LTNPs preferentially 
targeted the highly conserved p24 region of Gag.  While the magnitude of T cell responses to 
Gag (particularly the p24 region of Gag) in the LTNP women was significantly inversely 
associated with plasma viral loads at the same time point; no correlation was observed in 
individuals who were acutely infected with HIV.  No association was observed between the 
breadth of HIV-specific T cell responses and plasma RNA viral loads. 
Conclusion.  In this study, the magnitude and breadth of the Gag and Nef-specific responses 
shortly after HIV infection were not associated with initial control of HIV replication (although 
the cohort was very small).  Both the magnitude and breadth of HIV-specific responses increased 
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1.1 Overview of the HIV-1 epidemic 
From recent surveys, there are an estimated 33.3 million people infected with human 
immunodeficiency virus (HIV) globally (UNAIDS, 2010).  An estimated 2.6 million new HIV 
infections were reported in 2009, which was 21% fewer than the highest incidence of 3.2 million 
reported in 1997 (Figure 1.1).  The majority of the countries that recorded a lower rate in new 
infections were in Sub-Saharan Africa.  This region still bears an alarming proportion of the 
global epidemic, however, accounting for 68% of people living with HIV.  The UNAIDS report 
(2010) has cited that this decline in incidence is due to the advances in anti-retroviral therapies 
and efforts of improving access to treatment.  The risk of HIV-1 transmission per heterosexual 
contact is high in low income countries (Boily et al., 2009).  In contrast, an unprecedented 
resurgence of new infections were evident in several high income countries in Eastern Europe 
and Central Asia (Figure 1.2), and these were predominantly among men who have sex with men 







Figure 1.1 The total number of individuals globally who were newly infected with HIV.  This graph 
shows the course of estimated incidence over a period of 20 years.  The red line indicates the new 
estimates in millions while the dotted line indicates the plausible bounds (taken from UNAIDS, 2010). 
 
South Africa is one of the countries that showed a decline in HIV incidence in the most recent 













2001 (Figure 1.2).  South Africa, however, still has highest number of people in the world living 
with HIV with an estimated 5.2 million people infected.  Furthermore, the prevalence in females 
within the age group 15-29 is almost 3–fold higher than the men in the same age group (RSA 
HIV/AIDS Progress Report, 2010; Figure 1.3).  It has been speculated that the reason for the 
elevated incidence in young women compared to young men in South Africa is due to 
intergenerational sexual behavioral patterns where the women are much younger than their male 
sexual partners, making it more likely that these younger females are defenseless when 
negotiating the use of condoms in their older male partners (Parker et al., 2007; Shishana et al., 
2009; Mercer et al., 2009).  The recent success by a South African research team showing the 
39% efficacy of a 1% Tenofovir-based microbicide gel has provided optimism and 
empowerment to young women who now have the ability to control prevention against HIV 
(Abdool-Karim et al., 2010). 
 
     
Increasing  > 25%
Stable
Decreasing  > 25%
Not included in analysis
 
 
Figure 1.2 Global trends of changes in the incidence rate of HIV infections between 2001 and 2009.  
The map includes trends from 60 countries where reliable diagnostic tests were used to determine the HIV 
incidence rate and 3 countries where peer reviewed of publications with incidence trends were available.  
Incidence rates could not be concluded for countries such as Brazil, China and Russia Federation due to 














Figure 1.3 The 2008 survey of HIV prevalence by gender and age in South Africa.  Generally, 
women had a higher HIV prevalence than men with the exception of age groups 40-44, 50-44 and the 60+ 
groups.  This may be an indication of intergenerational sexual practice where younger women are easily 
pressurized in not using condoms (adapted from RSA HIV/AIDS Progress Report, 2010). 
 
1.2 Phylogenetics of HIV 
HIV belongs to the Lentivirus genus and is a subfamily member of the Retroviridae group of 
viruses.  HIV-1 is closely related to simian immunodeficiency virus (SIV) from chimpanzees and 
HIV-2 is closely related to SIV from sooty mangabeys (Hirsch et al., 1989; Gao et al., 1999).  Of 
these two HIV subtypes, HIV-1 is more prevalent globally whereas HIV-2 is endemic in West 
Africa and sporadically in the rest of the world.  HIV-2 is also thought to be less pathogenic and 
is associated with a slower rate of disease progression than HIV-1 (reviewed by Rowland-Jones 
and Whittle, 2007). 
HIV-1 has been further divided into three distinct groups:  M (majority), N (non-M and non-O) 
and O (outlier) as shown in Figure 1.4.  HIV-1 group M can be further sub-divided into subtypes 
or clades, namely A, B, C, D, F, G, H, J and K (Figure 1.4).  HIV-1 subtype C is the most 
prevalent clade globally and the most dominant clade found in South Africa and Asia (Hemelaar 
et al., 2006).  HIV-1 subtype C accounts for 50% of the total global infection, whereas subtypes 













H, J and K together account for only 0.9% of infections globally (Hemelaar et al., 2006; Figure 
1.5). 
 
Figure 1.4 Phylogenetic tree of HIV-1 and SIV chimpanzee.  The tree shows the three groups of HIV-1 
M (main), N (non-M and non-O) and O (Outlier) as well as the close relationship between HIV-1 and 
SIVcpz.  HIV-1 M can be further subdivided into clades: A, B, C, D, F, G and K (not represented in this 


















Figure 1.5 Global distribution of HIV-1 subtypes and circulating recombinant forms in 2004.  The 
proportions of subtypes, A, B, C, D, F, G, H, J, K and recombinants AE, AG and other are represented in 













1.3 Organization of HIV 
HIV is an enveloped retrovirus with an RNA genome of 10 kilobases.  The outer envelope of 
HIV is comprised of a phospholipid bilayer derived from the host cell membrane (Figure 1.6).  
Protruding from the envelope are spikes, composed of a trimeric complex made up of the 
hetrodimer glycoproteins gp120 (spike cap) - gp41 (spike stem) (White et al., 2010).  The inner 
core of the virus consists of viral enzymes, reverse transcriptase and proteins as well as two 
identical singular strands of RNA, each of which encodes copies of nine genes.  Three of these 
nine genes (Gag, Pol and Env) encode structural proteins whereas the other six are regulatory 
genes (Vif, Rev, Nef, Tat, Vpu, and Vpr) and are involved in the control of viral replication.  The 
















Figure 1.6 Structure of HIV.  The outer layer consists of a phospholipid bilayer from which protrudes 
glycoproteins, gp41 and gp120.  The core structure has enzymes, reverse transcriptase and protease as 
well as two single stranded RNA molecules which encode for the structural proteins (Gag, Pol and Env) 













1.4 HIV life cycle in host cells 
The HIV-1 replication cycle in host cells is summarized in Figure 1.7.  For HIV-1 entry into a 
target cell, it requires binding of HIV gp120 to host cells expressing CD4; including CD4+ T 
lymphocytes, monocytes, macrophages and dendritic cells (reviewed by Hladik and McElrath, 
2008).  Binding of CD4 to gp120 induces a conformational switch in gp120 which facilitates 
gp120 binding to a chemokine co-receptor on the host cell membrane (Doms and Moore, 2000).  
Several chemokine co-receptors have been identified but the most common ones used by HIV-1 
are either CXCR4 or CCR5 (reviewed by Wu, 2010).  Following attachment, the fusion peptide 
of gp41 allows for the fusion of the viral cell membrane and the host cell membrane (Briggs et 
al., 2000).  The process of uncoating of the viral particle occurs next, whereby the viral core is 
released into the cytoplasm of the target cell, freeing the viral RNA.  Viral RNA is converted 
into proviral DNA by the action of reverse transcriptase and intergrase, and this is followed by 
the formation of a hybrid RNA/DNA double helix.  The RNA is broken down by ribonuclease 
and polymerase reconstructs the complementary DNA strand to form the double helix DNA 
molecule, which is transported to the nucleus and incorporated into the host genome by the 
action of intergrase (reviewed by Fanales-Belasio et al., 2010).  This double helix DNA is called 
a provirus and can remain dormant for long periods of time and in this way a host cell can 
remain latently infected (Zhou et al., 2005). 
Transcription of proviral DNA into mRNA can only take place once the host cell is in an 
activated state (reviewed by Fanales-Belasio et al., 2010).  The initial process of transcription 
involves the synthesis of regulatory HIV-1 proteins, followed by the later stage of expression of 
structural proteins.  Once new viral particles are formed, they migrate towards the cell membrane 
where proteins from the host cells such as cholesterol and phospholipids are included and the 






























Figure 1.7 HIV replication cycle in host cells.  To infect a new host cell, HIV first interacts with 
host cell CD4 using gp120 and gp 41.  This interaction causes a conformational change in gp120 
which allows interaction with a chemokine co-receptor, leading to fusion and entry of the virion 
into the host cell.  Following entry, viral RNA is copied into DNA by reverse transcriptase which 
is incorporated into the host DNA.  At this stage the integrated DNA is known as a provirus 
which is transcribed into mRNA.  Translation and assembly of new HIV structural proteins 
follows by using the proteins from the host to form virions which bud from the cell membrane. 
 
1.5 The natural history of HIV infection 
Once HIV has infected a new human host, the clinical disease course that follows HIV-1 
infection can be divided into three distinct clinical stages:  the acute phase of HIV infection, the 
chronic phase of HIV infection in the absence of anti-retroviral therapy, and finally acquired 
immune deficiency syndrome (AIDS) associated with a decline in CD4+ cells to <200 cell/µl in 



















Figure 1.8 Kinetics of HIV disease progression in the absence of anti-retroviral treatment.  The 
initial extraordinary rise in HIV load in the acute phase is followed by an increase in HIV-specific CTLs 
and a decrease in the number of CD4+ T cells.  HIV RNA load is reduced within 1-2 months and 
maintained at a new lower threshold by the immune response.  The lower HIV RNA load is concomitant 
with an increase in CD4+ T cell numbers, and at 2 to 3 months seroconversion occurs as HIV-specific 
antibodies appear.  This new symptomatic phase is predominantly maintained for a number of years. A 
slow decrease in the CD4+ T cell counts leads to the onset of AIDS elevating susceptibility to other 
pathogenic infections.  This is followed by an increase in the virus load, along with a decrease in the HIV-
specific CTL, and neutralizing antibodies. 
 
The acute phase of HIV infection represents the first interaction between the human immune 
system and the incoming virus (Johnston and Fauci, 2008; Yang et al., 2008; Boutwell et al., 
2010).  HIV-specific T cells are detected within 4-6 weeks of infection while HIV-specific 
binding antibodies (associated with HIV seroconversion) generally appear within 1-3 months 
post-infection (Kahn and Walker, 1998).  The emergence of HIV-specific T cells is associated 
with a marked decline in plasma viremia which eventually stabilizes between 6 and 12 months of 
infection to a level known as viral set point (Boutwell et al., 2010).  HIV set point is the level to 
which the host immune response can control plasma viremia: the lower the viral set point, the 
better prognosis for the long term survival of an infected individual (Mellors et al., 2007; Streeck 














The chronic or asymptomatic phase follows and can last for many years, where there is constant 
viral replication with gradual but irreversible loss of CD4 T cells (Centlivre et al., 2007).  In the 
absence of anti-retroviral therapy, the final stage, AIDS, occurs when the majority of CD4 T 
cells have been destroyed and the immune system can no longer mount effective responses 
against opportunistic pathogens (Centlivre et al., 2007). 
1.5.1. Clinical course of acute HIV infection 
Acute HIV infection refers to the period immediately after productive infection where HIV RNA 
is detectable in blood but HIV-specific antibodies may not yet be detectable.  Acute HIV-1 
infection is characterized by a dramatic increase in titers of plasma HIV and significant loss of 
CD4 T cells (Khan et al., 1998), particularly in the gut-associated lymphoid tissue (Mattapallil et 
al., 2005).  Although transient, clinical symptoms associated with acute HIV infection do occur 
shortly after exposure (Machala et al., 2004), including fever, rash, headaches, myalgia 
lymphadenopathy, pharangitis, arthalgia, gastrointestinal distress, night sweats, and oral or 
genital ulcers (Schacker et al., 1997).  The time from infection to the onset of first clinical 
symptoms is usually 2-6 weeks, with seroconversion starting 1-3 weeks later (Petersen et al., 
1994). 
Fiebig et al. (2003) has defined six clinical stages of acute HIV infection based on the presence 
or absence of HIV-1 specific antigens or antibodies in the blood of an HIV-infected individual 
(Figure 1.9).  Stages I–VI are determined by the sequential gain of positive reactions to viral 
RNA (PCR), p24 and p31 (ELISA) and viral antibodies (western blot).  Prior to the Fiebig stage 
I, is the eclipse phase, which lasts for 0-10 days from viral exposure (Khan and Walker 1988; 
McMichael et al., 2010).  During this phase, there is no detectable viral RNA in the blood.  
Following the eclipse phase, viral RNA levels rise exponentially in plasma, peaking at about 28-
30 days (Fiebig stages I-IV) and then subsequently declining (Fiebig stage V) until a plateau is 
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Figure 1.9 Fiebig staging of acute HIV infection.  Fiebig et al. (2003) defined a six-stage (I-VI) 
classification system for acute HIV infection using the stepwise gain in positivity for the detection of 
HIV-1 specific antigens and antibodies.  The period between 0-10 days is known as the eclipse phase.  
This is followed by an exponential increase in plasma viral RNA levels which peak between 21 and 28 
days post-infection (Fiebig stages I – III).  After the initial burst in viremia, a slower decrease in viral 
RNA follows at approximately 100 days post infection (Fiebig stages IV – V).  Fiebig Stage VI is the 
start of the early chronic phase and this usually occurs when the viral load begins to plateau (McMichael 
et al., 2010).  
 
1.5.2. CD4 T cell counts and viral load fluctuations during acute infection 
CD4 T cell counts in blood and HIV plasma load measurements are independently strong 
predictors of HIV disease progression, however the combination of the two can strengthen the 
monitoring and evaluation of patients infected with HIV during all stages of disease (Mellors et 
al., 1997).  It is well documented that the initial burst of viremia reaches a peak of approximately 
105-107 RNA copies/ ml with a simultaneous profound loss of CD4+ T cells (Daar et al., 1991; 
Clark et al., 1991).  The fast decline of CD4+ T cells is followed by a slower rate after 5 to 6 














plasma viral load was shown to be inversely associated with CD4+ T counts (Gray et al., 2005; 
Novitsky et al., 2009).  Furthermore, during acute HIV-1subtype C infection, Novitsky et al. 
(2009) found that individuals whose peak viral loads declined fast had lower viral load at set 
point and better preservation of CD4 T cell numbers during the course of infection than 
individuals whose viral loads declined more slowly. 
1.5.3. CD4 T cell counts and viral load fluctuations during chronic infection 
Approximately six months after infection, most individuals reach an asymptomatic phase with a 
viral set point often lower than 20,000 RNA copies per ml (reviewd by Levy, 2009).  However 
the viral set point value may vary up to a 1000 fold between patients (Mellors et al., 1996; de 
Wolf et al., 1997).  Following ten years of infection, about 50% of untreated HIV-infected 
individuals will drop their CD4 T cell counts below 350 cells per µl and start exhibiting signs of 
other opportunistic infections (progressors; Buchbinder et al., 1994 and reviewed by Levy, 
2009).  A small percentage of individuals (~5%) are able to maintain CD4 T cell counts above 
500 cells per ml for several years and are know as long term non-progressors (LTNPs).  Less 
than 1% of these individuals are able to maintain low viral load of <50 copies/ml for many years 
and have been defined as elite controllers (ECs).  Most of these ECs exhibit very low rates of 
CD4 decline (reviewed by Blankson, 2010).  Moreover, elite controllers characteristically have a 
slower rate of disease progression than LTNPs who inevitably develop progressive HIV-1 
(Rodés et al., 2004; Blankson, 2010).   
Several studies have suggested that LTNPs and ECs may be infected with a defective virus 
(Alexander et al., 2002; Calugi et al., 2006), which partially explains their ability to control their 
viraemia.  However, others have shown that, in some instances, these individuals could be 
infected with a pathogenic virus.  Miura et al. (2008) showed by viral sequencing that there were 
no large deletions present in 60 ECs which reveal that these virus are replication-competent.  A 
subsequent study showed that a pathogenic virus from a progressor who developed AIDS was 
transmitted to an EC (Bailey et al., 2008; reviewed by Blankson 2010). 
Similar to acute infection, there is evidence of inverse correlation between CD4 T cell count and 
viral load during chronic untreated infection (Mendiratta et al., 2009).  In a recent review, it was 













viral load less than 75 RNA copies per ml had met the clinical definition of AIDS, with CD4 T 
cell counts less than 350µl per ml.  This suggests that ECs with low viral loads in the absence of 
therapy are not always able to maintain their CD4 T cell counts during the course of infection 
(Poropatich and Sullivan 2011).  
 
1.6 HIV-1 specific immune responses  
Humoral and cellular immune responses have been implicated in control of HIV infection and 
HIV-specific antibody and T cell immune responses are readily detected in HIV-infected 
individuals (Figure 1.8; Fiebig et al., 2003).  HIV-specific CD8 T cell responses during acute 
infection emerge as early as two weeks post-infection while neutralizing antibodies are only 
detectable several months later (Figure 1.8; Pilgrim et al., 1997; Gray et al., 2007).  Whereas 
antibodies generally recognize unprocessed conformational or linear epitopes of HIV, T cell 
immunity against HIV requires intracellular processing of HIV in antigen presenting cells and 
presentation of short HIV linear peptides bound to Major Histocompatibiliy Complex (MHC) or 
human leukocyte antigen (HLA) molecules on the surface of antigen presenting cells 
(Zinkernagel and Doherty, 1997).   
1.6.1. Role of HIV-specific antibody responses in the control of HIV-1 infection 
HIV-specific binding antibodies are generally detectable within weeks of infection and are the 
basis of the Rapid test used to diagnose infection with HIV (HIV seroconversion; Figure 1.8; 
Pilgrim et al., 1997; Gray et al., 2007).  HIV-specific antibodies capable of neutralizing the virus 
are generally only detectable months after the first binding antibodies are detected.  This lag in 
the development of neutralizing antibodies has also been reported for SIV in macaques (Reimann 
et al., 1994; Montefiori et al., 1996).  No correlation was found between the emergence of HIV-
specific neutralizing antibodies following infection and decline in viremia during acute infection, 
even though binding Env-specific antibodies were detectable as early as two weeks after onset of 
symptoms (Aasa-Chapman et al., 2004; Gray et al., 2007).  This has lead many to speculate that 
neutralizing antibodies against HIV are not important in the initial control of HIV infection.  It is, 
however, likely that anti-HIV antibodies would be protection against infection if they were 













Some studies have shown that neutralizing antibodies develop more frequently in LTNPs than 
progressors (Cecilia et al., 1999) while others show that they are not (Pereyra et al., 2008; Doria-
Rose et al., 2010).  Pereyra et al. (2008) reported that ECs had lower levels of heterologous 
neutralizing antibodies than individuals with higher viral loads.  Furthermore, Blankson et al. 
(2010) showed that individuals with very low levels of virus (using very sensitive assays) had the 
lowest concentration of neutralizing antibodies suggesting that the neutralizing antibodies did not 
contribute to the maintenance of low viral load. 
1.6.2. Immune control by CTLs during acute HIV-1 infection. 
In contrast to antibodies, there is a substantial amount of evidence to suggest that CD8+ 
cytotoxic T lymphocytes (CTLs) are able to control HIV replication during acute infection.  
Koup et al. (1994) and Borrow et al. (1994) showed that the eradication of acute viral symptoms 
and concomitant reduction in viral load was temporarily associated with the emergence of HIV-
specific cellular immunity.  Subsequently, SIV-infected macaques in which CD8+ T cells were 
depleted prior to infection by CD8+ monoclonal infusion had higher viremia and accelerated 
disease course than immuno-competent macaques (Jin et al., 1999; Schmitz et al., 1999).  HIV-1 
specific cellular immune responses generated during early HIV infection appear to be key 
determinants of the rate of disease progression (Mellors et al., 1996; Allen et al., 2000; Streeck 
et al., 2009; Streeck and Nixon 2010). 
1.6.3. Characterization of HIV-1 specific immune responses during acute and chronic HIV 
infection 
While there is strong evidence that specific CTL responses are important in HIV control, a 
number of studies have reported inconsistent associations between magnitude and/or breadth of 
HIV-specific CTL responses and viral load.  Some studies reported an inverse correlation 
between HIV specific T cell responses with plasma viral load (Ogg et al., 1998; Betts et al., 
1999; Buseyne et al., 2002; Chouquet et al., 2002; Edwards et al., 2002) where others observed a 
positive correlation (Masemola et al., 2004).  In contrast, Addo et al. (2003) and Novitsky et al. 
(2003) have shown no relationship between HIV specific T cell responses and plasma viral load.  
With the use of 410 overlapping peptides spanning the entire HIV-1 consensus B genome 
including multiple ethnic groups, Frahm et al. (2004) found that Gag- and Nef-specific responses 













of T cell responses and viral load.  Masemola et al. (2004) in subtype C infection (mixture of 
early and chronic cohort) and Lichterfeld et al. (2004) in subtype B infection (primary cohort) 
showed that Nef was the most frequently targeted of all HIV proteins although both studies 
found no correlation between viral load and the breadth of HIV-specific responses and only a 
weak correlation between viral load and the magnitude of responses.  In more recent longitudinal 
studies of acute and early infection, it was confirmed that Nef-specific responses were immuno-
dominant (Turnbull et al., 2009; Mlotshwa et al., 2010) 
It was also observed that early HIV-specific T cell responses during acute infection were lower 
in magnitude and directed against only a small number of epitopes than those detected during the 
chronic infection which were also broader (Dalod et al., 1999; Altfeld et al., 2001; Yu et al., 
2002; Addo et al., 2002; Turnbull et al., 2009).  In contrast, in a longitudinal study during 
chronic infection, the sequence evolution of CD8 T cell epitopes remained relatively constant 
over time, despite the continued persistence of CD8 T cell response (Koibuchi et al., 2005). 
Several of the abovementioned studies employed the IFN-γ ELISPOT assay which generally 
does not distinguish between CD4 and CD8 T cell responses unless purified CD8+ or CD4+ T 
cell populations are used in an experiment.  In a study where CD8 cells were depleted, however, 
no correlation was found between the magnitude or breadth of HIV-specific CD4+ T cell 
responses and viremia (Lichterfeld et al., 2004).  Betts et al. (2001) reported a similar finding for 
CD4+ T cells using intracellular cytokine staining (ICS) and flow cytometry but showed a 
positive correlation between the total frequency of HIV-specific CD8+ responses and viral load. 
Only a few recent studies have characterized the kinetics of HIV-specific T cell immune 
responses longitudinally following acute phase of infection (Turnbull et al., 2009; Goonetilleke 
et al., 2009; Mlotshwa et al., 2010).  All three studies showed that specific T cell responses were 
not static but expanded and contracted in subsequent waves resulting in shift in the epitope 
immunodominance (Turnbull et al., 2009) and temporal patterns due to viral sequence variance 
and recognition invariant viral epitopes (Mlotshwa et al., 2010).  In addition CD8+ T cells–
mediated killing of HIV-infected target cells were involved much earlier during acute infection 














1.7 Immune escape from HIV-specific CTLs during acute and chronic HIV 
infection 
Although CTLs responses play an important role in the initial control of HIV replication and 
disease progression, their ability to control HIV replication is impacted by the appearance of 
viral escape mutations (Moore et al., 2002).  CTLs recognize 8-11 amino acid long peptides 
presented by HLA class I molecules (reviewed by Yewdell et al., 2003).  Because CD8+ T cell 
immunity is dependent on recognition of antigenic peptides bound to specific HLA class I 
molecules, the “fit” of these peptides into HLA binding grooves directly influences the ability of 
a particular T cell to respond to its cognate antigen.  Any alteration or mutation within the 
foreign peptide or the antigenic binding cleft of the MHC molecule can alter T cell recognition 
and this is a mechanism used by some viruses to evade T cell immunity (Moore et al., 2002).  
The loss of viremic control during HIV infection is often associated with changes in the viral 
sequence targeted by effective CTL responses which results in the impairment of viral 
recognition by CTL or alteration in antigen presentation (Jones et al., 2004; Draenert et al., 
2004; Martinez - Picado et al., 2006). 
A study by O’Connor et al. (2002) in non-human primates showed that SIV is able to escape 
from the immune pressure being exerted by CTLs very early during infection by mutating the 
viral epitopes being targeted by the CTLs.  Many studies have since confirmed that this was a 
common feature of acute (Borrow et al., 1997; Cao et al., 2003; Allen et al., 2004; Bernardin et 
al., 2005; Li et al., 2007; Brumme et al., 2008; Wang et al., 2009) and chronic (Draenert et al., 
2004; Goepfert et al., 2008) HIV infection in humans. 
Certain HLAs have been associated with better HIV disease prognosis while others are 
associated with poor prognosis.  For example, HLA-B*27 and –B*5701, B*5703, B*5801 and 
B*-51 are associated with slow disease progression whereas HLA-B*35 and B*5802 are 
associated with rapid onset of AIDS (Gao et al., 2001; Carrington and O’Brien, 2003; Goulder 
and Watkins, 2008).  HIV epitopes that are restricted by the protective HLAs have been shown to 
be more frequently recognized than those that are restricted by the non-protective HLAs, 
irrespective of the stage of disease (Altfeld et al., 2006).  Furthermore, Frater et al. (2007) 
showed that individuals with HIV epitopes restricted by beneficial HLAs had more mutations 













restricted by the beneficial HLA were more frequently recognized which leads to higher 
selection pressure by CTL, which is evidenced by the higher rate of mutations. 
 
1.8 Impact of immune escape on HIV fitness 
Although there are numerous studies demonstrating that HIV is capable of mutating to escape 
CTL detection during both acute and chronic HIV infection (Goulder et al., 2004), each immune 
escape may result in some fitness cost to the virus (Li et al., 2007).  When a mutated virus is 
transmitted to a new host with different HLA alleles to the donor, epitopes that are no longer 
restricted by the HLA of the new host can revert to its original ancestral or wild type form at no 
fitness cost to the virus (Leslie et al., 2004; Crawford et al., 2007; Li et al., 2007).  When 
mutations do not revert after transmission in these hosts, however, this suggests that the mutation 
was not significant (Leslie et al., 2004; Draenert et al., 2004) or that viral fitness was restored by 
compensatory mutations (Kelleher et al., 2001; Schneidewind et al., 2007).  Futhermore, 
Chopera et al. (2008) showed that HLA mismatched individuals who have received transmitted 
viruses which have known attenuating mutations (T242N and A146X) as a result of coming from 
an HLA B*57/B*5801 donor (associated with LTNPs) exhibited effective control of vireamia 
following HIV infection. 
Certain parts of the HIV genome are highly conserved (such as the structural proteins of Gag; 
Edwards et al., 2002) but there are also regions that are highly variable and easy for the virus to 
mutate without significant fitness costs (such as envelope; Kiepiela et al., 2007).  Studies have 
shown that CTLs targeting conserved region of HIV are beneficial to the host because the virus 
is less likely to escape these CTL responses due to high fitness costs associated with escape in 
these regions (Martinez–Picado et al., 2006; Goepfert et al., 2008). 
 
1.9 Immunodominance in HIV-1 specific CTL responses 
Yu et al. (2002) described CTL responses directed against HLA-A*3 and HLA-B*7 restricted 
epitopes following acute infection in an individual that were conserved over a period of 34 













HLA-A*3+ and HLA-B*7+ also had CTLs targeting one or both of these HLA-A*3 and HLA-
B*7 epitopes during acute infection, suggesting that patterns in the development of 
immunodominant CTL responses exist. 
Streeck et al. (2009) investigated the relationship between the first immunodominant specific T 
cell responses during acute infection with those in chronic infection.  They showed that CTL 
responses developed in a hierarchical immunodominant pattern during acute infection and 
correlated with viral set point, and a slower rate of CD4 decline.  In contrast, these authors did 
not find a correlation between immundominant CTL responses during chronic infection and viral 
set point.  
Individuals who mount an immunodominant HIV-specific response at the onset of HIV-infection 
have been shown to have a greater chance of a having a lower viral set point than those who do 
not target immunodominant epitope during acute infection (Goonetilleke et al., 2009).  It is also 
possible to predict which HIV epitopes are likely to be targeted during HIV infection in 
individuals who have known HLA types (Streeck and Nixon, 2010).  For example, an individual 
who is HLA-B*27+ has an 81% chance of targeting the Gag KRWIILGLNK [KK10] epitope 
during acute infection and this drops to a 43% chance during chronic infection.  An individual 
who is HLA-A*30+ has a 25% chance of targeting Integrase KIQNFRVYY [KYY9] epitope 
during acute infection and an 80% chance of targeting this epitope during chronic infection. 
 
1.10 Importance of HIV-specific CTLs targeting Gag 
Early studies have shown that Gag-specific CTLs are associated with better viral control than 
CTL responses directed against other HIV proteins (Edwards et al., 2002; Novitsky et al., 2002; 
Buseyene et al., 2002; Masemola et al., 2004 and Ramduth et al., 2005).  These studies have 
suggested that this better control is because Gag is a highly conserved structural protein that does 
not tolerate escape mutations easily and in which mutations are often accompanied by substantial 
fitness cost to the virus.  In addition, and possibly as a result of it being so conserved, Gag also 













Kaushik et al. (2005) also showed that p24 was the most recognized region within Gag while 
Mendiratta et al. (2009) showed that the magnitude of Gag-specific responses correlated 
inversely with viral load whereas Nef-specific responses were not correlated with viral load.  In a 
large South African cohort of 578 untreated chronically HIV-infected participants, Kiepiela and 
colleagues (2007) showed that individuals who targeted Gag had significantly lower viremia than 
individuals who did not whereas individuals who targeted Env had significantly higher viremia 
than those that did not (Kiepiela et al., 2007).  This confirms that Gag-specific T cell responses 
are associated with effective control of viremia. 
HLA-B*57, one of the most protective HLA alleles, has been shown to restrict epitopes within 
the p24 region of Gag: TSTLQEQIAW [TW10], KAFSPEVIPMF [KF11] and ISPRTLNAW 
[IW9] (Goulder and Watkins, 2008).  TW10 is the most frequently targeted B57 restricted 
epitope during early infection and was also found to escape CTL pressure the most rapidly 
(Streeck et al., 2007; Brumme et al., 2008).  TW10 can also be presented by HLA B*5801, 
which is closely related to HLA B57 (Goulder et al., 1996).  The most common mutation within 
this B*57/B*5801 restricted epitope is T242N, which occurs rapidly during acute infection 
(Brumme et al., 2008) and is associated with a replication-incompetent virus (Martinez-Picado et 
al., 2006; Miura et al., 2009).  Individuals with T cell responses targeting the HLA B*27 epitope 
in Gag KRWIILGLNK (KK10) were also shown to control viremia whereas individuals who 
expressed the same HLA but failed to target KK10 typically had high viremia (Goulder and 
Watkins, 2008).  These experiments show the strong impact of HLA-B phenotype and the 
targeting of Gag has in the control of HIV disease progression.  
 
CONCLUSION 
Acute HIV infection is associated with the emergence of HIV-specific CTL responses within the 
first few weeks after infection that are associated with the drop in peak viraemia.  Studies have 
shown that targeting of HIV Gag responses early during HIV infection is associated with better 
control of viral load.  Studying HIV-specific T cell response kinetics during the course of HIV 
infection may give important insight into the type of CTL specificities associated with better 













RATIONALE OF THIS STUDY 
The need to develop an efficacious HIV vaccine to either protect from or attenuate HIV-
associated disease progression is paramount.  Better understanding of the correlates of protective 
T cell immunity associated with control during HIV infection is central to effective vaccine 
design.  Previous studies have suggested that immune responses mounted early during HIV-
infection determine the level of control of viremia (HIV set point) achieved in an individual 
(Mellors et al., 1996; Allen et al., 2000; Rosenberg et al., 2000; Streeck et al., 2008). 
The correlation between HIV set point and the rate of disease progression (Streeck et al., 2009) 
further suggests that HIV-specific immune responses generated during acute/early infection are 
important to understand.  In this study, the magnitude and breadth of cellular immune responses 
against HIV Gag and Nef were monitored longitudinally in acutely HIV infected individuals 
through to their chronic stages of infection by IFN-γ ELISPOT. 
 
AIM 
To investigate the relationship between HIV disease progression and both the magnitude and 
persistence of HIV-1 subtype C Gag and Nef-specific T cell responses during acute through to 
chronic HIV infection. 
 
Specific Objective 1 
To compare the magnitude and breadth of HIV-1 Gag- and Nef-specific T cell responses 
generated during acute HIV infection with those from chronic HIV infection. 
Hypothesis: HIV-specific immune responses during acute infection will be narrower than 
responses mounted during chronic infection but will broaden with increasing disease 
progression.  HIV-specific immune responses in long-term non-progressors will be higher in 














Specific Objective 2 
To investigate the relationship between clinical markers of HIV disease progression (plasma HIV 
RNA load and blood CD4 T cell counts) and the magnitude and/or breadth of HIV-specific 
responses in individuals who are acutely infected with HIV compared to long-term non 
progressors. 
Hypothesis: Individuals with the highest magnitude and breadth of responses to HIV Gag and 
Nef in acute infection and to Gag only in LTNPs will show better ability to control HIV disease 
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2.1 Description of cohort 
Five hundred HIV negative individuals from Gugulethu, Cape Town were enrolled in an 
observational vaccine preparedness study headed by Dr Linda-Gail Bekker from the 
Desmond Tutu HIV Foundation and funded by the International AIDS Vaccine Initiative 
(IAVI).  University of Cape Town Ethics approval for the study was obtained and all 
participants gave informed written consent to participate in the study and offered voluntary 
risk reduction counselling and HIV testing monthly for 12 months.  Each participant was 
screened for HIV antibodies and RNA at each monthly visit to determine the HIV incidence 
rate in this community.  For the purposes of this study, recent HIV infection was defined by 
at least two positive rapid HIV antibody tests and/or a positive HIV RNA test.  The last 
documented negative HIV antibody test had to have been within 3 months of enrolment.  
 
Of these 500 HIV negative participants, 7 became infected with HIV during follow-up and 
the HIV incidence was calculated to be 1.4%.  Upon HIV infection, individuals were enrolled 
into an acute HIV-infection cohort and followed up at enrolment, 1 month, 3 months, 6 
months, 12 months, 18 months, 24 months and 30 months post-infection.  In this study, 
enrolment was considered acute infection, 1- 3 months were considered to be early infection; 
while 6-30 months were considered to be chronic HIV-infection. 
  
In addition, 9 individuals who were considered to be long-term non-progressors (who had 
been infected with HIV for >5 years and maintained CD4 counts >300 cell/ µl in the absence 
of therapy) were enrolled from the Nyanga Day Hospital in Cape Town for comparison.  All 
participants from the acute infection and long-term non-progressor (LTNP) cohorts were not 
on highly active anti-retroviral therapy (HAART) at the time of study and clinical data was 
available from both cohorts.   
 
2.2 Sample collection  
At each visit, 80 ml whole anti-coagulated blood was collected by venipuncture into Acid 
Citrate Dextrose (ACD) vacutainer tubes (BD Bioscience) from each of the study participants 
by the study nurse.  All blood samples were processed immediately upon arrival in the 
laboratory.  Fresh peripheral blood mononuclear cells (PBMCs) were used for assays from 













An additional 5ml EDTA (Ethylenediaminetetraacetic acid; BD Bioscience) sample was 
collected from each participant for CD4 counts. 
 
2.3 Sample handling  
All laboratory procedures were done in a Biohazard Class II safety cabinet.  Protective 
gowns, gloves and eyewear were worn when handling samples.  All waste was placed in 
disinfectant before it was autoclaved and appropriately disposed of.  Regular quality control 
was done on all instruments and Good Laboratory Practice was strictly adhered to at all 
times. 
 
2.4 Blood CD4 counts and plasma viral load determination 
CD4 counts were performed on all individuals at each visit and done by the National Health 
Laboratory Services at Groote Schuur Hospital and Green Point, Cape Town.  Viral loads 
were determined in plasma samples from acutely and LTNP HIV-infected women using the 
NucliSENS EasyQ HIV 1 Version1.2 assay and performed by the National Health Laboratory 
Services at Groote Schuur Hospital.  This assay is reported to have a detection limit of >50 
HIV RNA copies/ml.  Plasma was derived from ACD anti-coagulated whole blood following 
Ficoll density gradient centrifugation as previously reported (Gumbi et al., 2008) and stored 
at -80oC until analysis.  
 
2.5 Isolation of peripheral blood mononuclear cells  
PBMCs were isolated from whole blood by Ficoll gradient centrifugation using Leucosep 
tubes (Greiner Bio-One).  Leucosep tubes contain circular porous discs which stabilize the 
gradient interface and allow for easy harvesting of PBMC without red blood cells 
contamination.  Initially, Histopaque (Sigma-Aldrich) and wash buffer (1% Foetal Bovine 
Serum in Phosphate buffered saline; Gibco) were equilibrated to room temperature.  
Histopaque (15 ml) was aliquoted onto the barrier of the 50ml Leucosep tubes.  Leucosep 
tubes were then centrifuged (Heraeus 1.0R Megafuge) at 1257g for 1 min, which allowed the 
Histopaque to move through the barrier to the bottom of the tube.  Histopaque is a viscous 
density gradient medium consisting of a mixture of polysucrose and sodium diatrizoate 
solution (Bøyum, 1968).  The principle of this method is based on differential densities of 













Histopaque and a centrifugal force is applied, lighter mononuclear cells are held at the plasma 
interface while heavier erythrocytes and granulocytes gravitate to the bottom of the gradient 
(Bøyum, 1968).   
In this study, well mixed anti-coagulated blood was carefully poured onto the Leucosep 
barrier and the tubes were centrifuged for 15 minutes at 1257g (Heraeus 1.0R Megafuge).  
Figure 2.1 outlines the principle of this procedure and describes the position of the PBMC 
layer following centrifugation.  The PBMC layer (Figure 2.1) was harvested using a plastic 
sterile disposable pasteur pipette and transferred to a new sterile 50ml tube (Greiner Bio-one) 
for washing.  The wash tube was topped up with wash buffer (1% Foetal Bovine Serum in 
Phosphate buffered saline) and centrifuged 320 x g (1200rpm).  The pelleted cells were 
resuspended in R10 [10% Foetal Bovine Serum in RPMI 50U penicillin, 50mg/ml 
streptomycin, 50mg/ml glutamine and 0.8mg/ml Fungin] and counted using a Guava 






Figure 2.1 Whole blood separation by Histopaque density gradient centrifugation.  The tube on 
the left show layering of mixed whole blood onto the leucosep barrier which is underplayed by 
Histopaque.  The tube on the right shows the result of centrifugation at 1257g for 15 mins.  After 
centrifugation, whole blood has separated into a plasma phase (top), then the layer of PBMCs (also 















2.6 Counting of PBMCs 
To count PBMCs, 10µl PBMCs were diluted with 190 µl ViaCount reagent (1:20 dilution; 
Guava Technologies) and incubated at room temperature for 8 minutes.  Viacount reagent 
contains a combination of two DNA-binding dyes with differential permeabilities allowing 
the distinction between viable and non viable cells.  The stained cell suspension was vortexed 
before counting.  A Guava automated cell counter (Gauva Technologies) was used to 
determine the number of PBMCs isolated.  A minimum of 1000 cells were acquired and 
Cytosoft 2.1.4 software was used to determine the cell concentration.  For ELISPOT, PBMCs 
were adjusted to 2x106 cells/ ml.  All remaining PBMCs were frozen in liquid nitrogen for 
later experiments. 
 
2.7 Cryopreservation of PBMC 
Cryopreservation allows long term storage of cells in liquid nitrogen with minimal damage to 
the cells upon recovery.  Dimethyl Sulfoxide (DMSO; Sigma Aldrich) is traditionally used as 
a cryo-protectant which reduces the formation of ice crystals during the freezing process thus 
lowering the ionic stress of the cells (Maecker et al., 2005). 
 
PBMCs which were not used immediately for ELISPOT were suspended in a specific volume 
of neat Foetal Bovine Serum at a final concentration of 20x106 cells/ ml.  An equal volume of 
cold freezing medium (20% DMSO in FBS) was added dropwise while continuously gently 
mixing the content.  The cell suspension was immediately dispensed in volumes of 1 ml into 
pre-chilled labelled 2 ml cryovials (Greiner Bio-one), giving a final concentration of 10 x 106 
cells/ml, placed into a ‘Mr Frosty’ freezing container (Nalgene) and transferred to -800C 
overnight.  ‘Mr Frostys’ contain isopropanol which slows and controls the rate of freezing to 
–10C per minute.  The cryovials were then transferred to liquid nitrogen for long term storage 
(Cryo 200, Forma Scientific). 
 
2.8 Thawing of cryo-preserved PBMCs 
Thawing PBMCs involves rapid thawing of cells in a 37 ºC water bath until a piece of ice 
crystal is still visible in the vial.  Pre-warmed R1 (1% FBS in RPMI containing 50U 













wise while simultaneously mixing the content of the vial.  Once the vial was filled with R1, 
the content was transferred to a 50 ml centrifuge tube which was filled with R1.  The cell 
suspension was carefully mixed by inverting the tube 3 times and was centrifuged at 300 x g 
for 10 minutes.  The supernatant was discarded and cells were washed as before.  After 
washing, the cells were resuspended in the 10ml R20 (20% FBS in RPMI containing 50U 
penicillin, 50mg/ml streptomycin, 50mg/ml glutamine and 0.8mg/ml Fungin) and rested 
overnight at 37oC 5% CO2.  Resting PBMCs prior to functional analysis reduces the 
frequency of non-specific “background” IFN- γ responses measured by ELISPOT probably 
because cells triggered to undergo apoptosis following thawing would have died before the 
functional assay is performed (Letsch et al., 2003). 
 
2.9 Preparation of HIV-1 Subtype C Gag and Nef peptide pools 
HIV-1 subtype C Du 422 Gag and consensus Nef peptides were kindly provided by the NIH 
AIDS Reagent Program and Dr Clive Gray (National Institute of Communicable Diseases, 
Johannesburg, South Africa), respectively.  These HIV subtype C peptide sets are based on or 
are closely related to the consensus sequence of HIV-1 Gag and Nef subtype C proteins 
circulating in South Africa.  A total of 121 15-mer Gag peptides and 50 15-mer Nef peptides 
overlapping by 11 amino acids (Figures 2.2 and 2.3), which spanned the entire Gag and Nef 
proteins were used in this study.  These peptides were obtained in a lyophilised form and 
were reconstituted in 50µl DMSO (Sigma) to provide a final peptide concentration of 
20mg/ml which were stored in 10µl aliquots at -80°C.  From the Gag and Nef stocks, 
individual peptides were combined to form 5 pools and 33 matrices of Gag (Table 2.1) and 5 
pools and 10 matrices of Nef (Table 2.2).  These combined peptide pools and matrices were 
diluted with RPMI to a working concentration of 40µg/ml and arranged into pool/matrix sets 
stored at -80oC.  This design allowed for each peptide to be represented twice within an 
ELISPOT assay, once in the pool as well as once in the matrix.  This design also allowed 
each peptide to be tested without the need for 121 individual Gag and 50 individual Nef 
stimulations.  Pool 1 spanned HIV-1 Gag p17 (matrix protein); pool 2, 3 and 4 spanned the 
highly conserved HIV-1 Gag p24 protein (capsid protein) and pool 5 spanned HIV-1 Gag p15 

















p17 - MATRIX  p24 - CAPSID  p15 - NUCLEOCAPSID 
Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 
MAARASILRGEKLDK ADGKVSQNYPIVQNL MLKDTINEEAAEWDR VSILDIRQGPKEPFR PGHKARVLAEAMSQT 
ASILRGEKLDKWEKI VSQNYPIVQNLQGQM TINEEAAEWDRLHPV DIRQGPKEPFRDYVD ARVLAEAMSQTNSGN 
RGEKLDKWEKIRLRP YPIVQNLQGQMVHQA EAAEWDRLHPVHAGP GPKEPFRDYVDRFFK AEAMSQTNSGNIMMQ 
LDKWEKIRLRPGGKK QNLQGQMVHQAISPR WDRLHPVHAGPIAPG PFRDYVDRFFKTLRA SQTNSGNIMMQRSNF 
EKIRLRPGGKKHYML GQMVHQAISPRTLNA HPVHAGPIAPGQMRE YVDRFFKTLRAEQAT SGNIMMQRSNFKGPR 
LRPGGKKHYMLKHIV HQAISPRTLNAWVKV AGPIAPGQMREPRGS FFKTLRAEQATQEVK MMQRSNFKGPRRIVK 
GKKHYMLKHIVWASR SPRTLNAWVKVIEEK APGQMREPRGSDIAG LRAEQATQEVKNWMT SNFKGPRRIVKCFNC 
YMLKHIVWASRELER LNAWVKVIEEKAFSP MREPRGSDIAGTTST QATQEVKNWMTDTLL GPRRIVKCFNCGKEG 
HIVWASRELERFALN VKVIEEKAFSPEVIP RGSDIAGTTSTLQEQ EVKNWMTDTLLVQNA IVKCFNCGKEGHIAR 
ASRELERFALNPGLL EEKAFSPEVIPMFTA IAGTTSTLQEQIAWM WMTDTLLVQNANPDC FNCGKEGHIARNCRA 
LERFALNPGLLETSE FSPEVIPMFTALSEG TSTLQEQIAWMTSNP TLLVQNANPDCKTIL KEGHIARNCRAPRKK 
ALNPGLLETSEGCKQ VIPMFTALSEGATPQ QEQIAWMTSNPPIPV QNANPDCKTILRALG IARNCRAPRKKGCWK 
GLLETSEGCKQIMKQ FTALSEGATPQDLNT AWMTSNPPIPVGDIY PDCKTILRALGPGAT CRAPRKKGCWKCGKE 
TSEGCKQIMKQLQPA SEGATPQDLNTMLNT SNPPIPVGDIYKRWI TILRALGPGATLEEM RKKGCWKCGKEGHQM 
CKQIMKQLQPALQTG TPQDLNTMLNTVGGH IPVGDIYKRWIILGL ALGPGATLEEMMTAC CWKCGKEGHQMKDCT 
MKQLQPALQTGTEEL LNTMLNTVGGHQAAM DIYKRWIILGLNKIV GATLEEMMTACQGVG GKEGHQMKDCTERQA 
QPALQTGTEELKSLY LNTVGGHQAAMQMLK RWIILGLNKIVRMYS EEMMTACQGVGGPGH HQMKDCTERQANFLG 
QTGTEELKSLYNTVA GGHQAAMQMLKDTIN LGLNKIVRMYSPVSI TACQGVGGPGHKARV DCTERQANFLGKIWP 
EELKSLYNTVATLYC AAMQMLKDTINEEAA KIVRMYSPVSILDIR GVGGPGHKARVLAEA RQANFLGKIWPSHKG 
SLYNTVATLYCVHEK  MYSPVSILDIRQGPK  FLGKIWPSHKGRPGN 
TVATLYCVHEKIEVR    IWPSHKGRPGNFLQN 
LYCVHEKIEVRDTKE    HKGRPGNFLQNRPEP 
HEKIEVRDTKEALDK    PGNFLQNRPEPTAPP 
EVRDTKEALDKIEEE    LQNRPEPTAPPAESF 
TKEALDKIEEEQNKC    PEPTAPPAESFRFEE 
LDKIEEEQNKCQQKT    APPAESFRFEETTPA 
EEEQNKCQQKTQQAK    ESFRFEETTPAPKQE 
NKCQQKTQQAKAADG    FEETTPAPKQEPIER 
QKTQQAKAADGKVSQ    TPAPKQEPIEREPLT 
QAKAADGKVSQNYPI    KQEPIEREPLTSLKS 
    IEREPLTSLKSLFGS 
    PLTSLKSLFGSDPLS 
    LKSLFGSDPLSQ 
     
 
Figure 2.2 Alignment of Gag subtype C Du422 peptide pools across the Gag protein within the 
HIV genome.  Gag regions represented are Gag p17 (matrix), Gag p24 (capsid) and Gag p15 
(nucleocapsid) split into a total of 5 pools.  The 121 peptides which span HIV Gag are 12-15 amino 
acids (aa) in length and each peptides overlap by 11 aa.  The peptide portions shown in black letters 

































Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 
GGKWSKSSIVGWPAV ALTSSNTAHNNPDCA YKAAFDLSFFLKEKG FPDWQNYTPGPGVRY NNCLLHPMSQHGMED 
SKSSIVGWPAVRERI SNTAHNNPDCAWLQA FDLSFFLKEKGGLEG QNYTPGPGVRYPLTF LHPMSQHGMEDADRE 
IVGWPAVRERIRRTE HNNPDCAWLQAQEEE FFLKEKGGLEGLIHS PGPGVRYPLTFGWCF SQHGMEDADREVLKW 
PAVRERIRRTEPAAE DCAWLQAQEEEEEVG EKGGLEGLIHSKRRQ VRYPLTFGWCFKLVP MEDADREVLKWVFDS 
ERIRRTEPAAEGVGA LQAQEEEEEVGFPVR LEGLIHSKRRQDILD LTFGWCFKLVPVDPR 147 DREVLKWVFDSSLAR 
RTEPAAEGVGAASQD 65EEEEEVGFPVRPQVP IHSKRRQDILDLWVY WCFKLVPVDPREVEE LKWVFDSSLARRHLA 
AAEGVGAASQDLDKH EVGFPVRPQVPLRPM RRQDILDLWVYHTQG LVPVDPREVEEANKG FDSSLARRHLAREKH 
VGAASQDLDKHGALT PVRPQVPLRPMTYKA ILDLWVYHTQGYFPD DPREVEEANKGENNC LARRHLAREKHPEYY 
SQDLDKHGALTSSNT QVPLRPMTYKAAFDL WVYHTQGYFPDWQNY VEEANKGENNCLLHP HLAREKHPEYYKDC 
DKHGALTSSNTAHNN RPMTYKAAFDLSFFL TQGYFPDWQNYTPGP NKGENNCLLHPMSQH EKHPEYYKDC 
 
 
Figure 2.3 Alignment of Nef subtype C peptide pools across the Nef protein within the HIV 
genome. [A] The proteins of the HIV genome.  [B] The domains of the HIV Nef protein.  [C] A total 
50 amino acid sequences which constitute the 5 peptide pools that span the Nef protein.  The peptide 
length was 15 ± 1 aa overlapping by 11aa indicated by the amino acids in black.  [D] The peptide 































Table 2.1 HIV-1 Gag peptide pool and matrix design 
 
  M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 
P1 1 2 3 4 5 6 7 8 9 10 11 
P2 31 32 33 34 35 36 37 38 39 40 41 
P3 50 51 52 53 54 55 56 57 58 59 60 
P4 70 71 72 73 74 75 76 77 78 79 80 
P5 89 90 91 92 93 94 95 96 97 98 99 
 
            
  M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 
P1 12 13 14 15 16 17 18 19 20 21 22 
P2 42 43 44 45 46 47 48 49       
P3 61 62 63 63 65 66 67 68 69     
P4 81 82 83 84 85 86 87 88       
P5 100 101 102 103 104 105 106 107 108 109 110 
 
            
  M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 
P1 23 24 25 26 27 28 29 30       
P2                       
P3                       
P4                       
P5 111 112 113 114 115 116 117 118 119 120 121 
 
 
The highlighted [ ] peptides = pool 1 spans HIV-1 Gag p17; [ ] peptides = pool 2, [      ] peptides 
= pool 3 and [ ] peptides = pool 4. Pools 2, 3 and 4 span the HIV-1 Gag p24.The [ ] peptides = 
pool 5 which span HIV-1 p15. An example of composition of a pool matrix; Pool 1 (P1) = 30 
peptides, 1-30 (Squares going across); matrix 1 (M1) = 5 peptides, peptides 1, 31, 50, 70 and 89 
(squares going down). 
 
 
Table 2.2 HIV-1 Nef peptide pool and matrix design 
 
  M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 
P1 1 2 3 4 5 6 7 8 9 10 
P2 11 12 13 14 15 16 17 18 19 20 
P3 21 22 23 24 25 26 27 28 29 30 
P4 31 32 33 34 35 36 37 38 39 40 
P5 41 42 43 44 45 46 47 48 49 50 
 
 
The highlighted [ ] peptides = pool 1; [ ] peptides = pool 2, [     ] peptides = pool 3; - [ ] 
peptides = pool 4 and [ ] peptides = pool 5.  An example of composition of a pool matrix; - Pool 1 
(P1) comprised peptides 1-10 (Squares going across) and matrix 1(M1) comprised of peptides 













2.10 Preparation of Cytomegalovirus-Epstein Barr virus-Influenza virus 
(CEF) peptide pools 
Cytomegalovirus (CMV), Epstein Barr virus (EBV) and Influenza virus (Flu) [CEF] peptides 
comprise a pool of immunodominant peptides containing common HLA (human leukocyte 
antigen)-restricted T cell epitopes from each of these viruses (Currier et al., 2002).  CEF 
peptides are useful positive controls for inclusion in ELISPOT assays because they have been 
shown to stimulate the production of IFN-γ from CD8+ T cells in individuals with HLA types 
common in most populations and most individuals are positive for at least one of these 
common viral infections (Currier et al., 2002).  These lyophilised peptides were kindly 
provided by Dr Clive Gray (NICD) and the NIH AIDS Reagent Program.  CEF peptides were 
initially reconstituted with 50 µl DMSO to form stock solution at a concentration of 20mg/ml 
which was stored at -800C.  From these stocks, RPMI was added to form working stock 
concentrations of 40ug/ml and were kept at -800C.  CEF was used at a final concentration of 
1µg/ well. 
  
2.11 Preparation of Phytohaemagglutinin (PHA) 
Phytohaemagglutinin (PHA; Sigma) is a mitogen which causes most cells to produce IFN-γ 
or proliferate and is therefore useful as a positive control.  PHA stocks (1mg/ml) were stored 
in 60µl aliquots at -200C.  PHA was used at a final concentration of 16 µg/ ml in the 
ELISPOT assay.  
 
2.12 IFN-γ ELISPOT assay 
The IFN-γ ELISPOT assay quantifies the number of T cells that produce IFN-γ in response to 
stimulation with recall antigen or mitogens (Streeck et al., 2009).  In this study, ELISPOT 
was performed as previously described (Bere et al., 2010) using fresh PBMCs from the acute 
HIV infection cohort and frozen PBMCs from the long-term non-progressor cohort 
(described in sections 2.5 and 2.7).  Initially, 96-well polyvinylidene diflouride (PVDF) 
plates (Multiscreen IP, Millipore) were coated with 50µL anti-IFN-γ monoclonal antibody 
clone 1-D1k (Mabtech) at a final concentration of 2µg/ml in PBS.  Plates were sealed with a 
plastic cover to prevent evaporation of the antibody and stored overnight at 4ºC.  Unbound 
antibodies were removed by washing each well three times with 200µl PBS.  In order to 













were blocked by incubating the plate with 200µl RPMI containing 10% FCS as a source of 
blocking protein for 2 hours at room temperature.  To each well of the coated plate, 50 µl of 
Gag, Nef or CEF peptides diluted in R10 at a final concentration of 1µg per ml were added, 
followed by 50 µl of PBMCs containing 105 cells (2x106/ml of R10).  The plating procedure 
of cells and peptides was done according to the representative plate layout shown in Table 
2.3.  Positive controls [including CEF peptides (final concentration of 1µg/well) and PHA 
(final concentration of 16 µg/ml) and negative controls [including medium alone and 
unstimulated PBMCs (background)] were included on each plate.  In addition, PBMCs from 
a donor with well-characterized CEF responses were included on each ELISPOT plate as a 
quality control across different plates and different assays (described in detail in Appendix 2). 
 
Plates containing PBMCs and peptides were incubated at 37ºC 5% CO2 for 18- 24 hours.  At 
the end of incubation, plates were washed six times with 0.01M PBS 0.05% Tween (Sigma) 
with an automated plate washer (ELX50, Bio-tek Instruments).  After washing, 50 µl 
biotinylated anti–IFN-γ monoclonal antibody (2µg/ml in 10% FBS/PBS; Mabtech) was added 
to each well and incubated for 2 hours at room temperature in the dark.  The plates were 
washed six washes with PBS Tween as before.  Subsequently 100 µl of Streptavidin 
horseradish peroxidase (Pharmigen) at a concentration of 2µg/ml in 10% FBS/PBS were 
added to each well and the plates were incubated for another hour at room temperature.  The 
plates were again washed six times with 0.01M PBS 0.05% Tween.  Finally, the IFN-γ spots 
were developed by the addition of 100 µL NovaRED substrate (Vector Laboratory) for 6 
minutes in the dark. 
 
The reaction was stopped by rinsing the plates with running tap water and plates were left to 
dry overnight in the dark.  Developed spots were quantified using the automated ImmunoSpot 
reader (Cellular Technology Ltd.) using ImmunoSpot Version 3 software.  After the spots 
were automatically quantified, a printout was generated which reflected a picture of the 


















Table 2.3 Representative figure of ELISPOT pipetting plan showing arrangement of Gag and 
Nef pools and matrices. 
 
  
1 2 3 4 5 6 7 8 9 10 11 12 
A MED GP1 GP2 GP3 GP4 GP5 GM1 GM2 GM3 GM4 GM5 GM6 
B GM7 GM8 GM9 GM10 GM11 GM12 GM13 GM14 GM15 GM16 GM17 GM18 
C GM19 GM20 GM21 GM22 GM23 GM24 GM25 GM26 GM27 GM28 GM29 GM30 
D GM31 GM32 GM33 NP1 NP2 NP3 NP4 NP5 NM1 NM2 NM3 NM4 
E NM5 NM6 NM7 NM8 NM9 NM10 
            
F BG BG BG 
    
PHA PHA PHA 
  
CEF CEF CEF 
 
 
Each square represents a well of a 96 well plate. HIV Gag (blue blocks) and Nef (green blocks) 
peptides were used in the acute HIV infection study while only Gag peptides were used in LTNP HIV 
infection study.  All peptides were represented twice, once in the pools and once in the matrix.  MED 
= Medium; GP= Gag Pool; NP = Nef pool; BG = Background; PHA = Phytohaemagglutinin and CEF 







Figure 2.4 A representative IFN-γ ELISPOT plate showing the number of spots counted next to 
each well generated by the automated Immunospot reader.  Each well corresponds to the square 
of the layout presented in Table 2.3.  From this result, spot forming units (SFUs) per well can be 
calculated by subtracting the background spots from the spots in the test wells (Table 2.4).  In this test 















2.13 Calculation of IFN-γ spot forming units (SFUs) and cut-offs 
To quantify IFN-γ T cell responses, the spots were expressed in a unit that enables the 
comparison of the magnitude and breadth of IFN-γ responses to HIV antigens Gag and Nef. 
ELISPOT spot forming unit (SFUs) per 106 PBMCs were calculated by subtracting the mean 
background number of spots obtained in negative control wells from the number of spots 
obtained in the test wells.  After background correction, SFUs were multiplied by a factor of 
10 since 105 cells were plated per well and the final results were expressed in SFU/106 
PBMC. 
 
For the acute cohort, in which PBMCs were assayed fresh, a net IFN-γ response of ≥50 
SFU/106 PBMCs was used as the cut-off for considering a response positive.  In support of 
this, Addo et al. (2002), Kaufmann et al. (2004) and Turk et al. (2008) have previously 
defined a positive response by ELISPOT as being >50 SFU/106 cells.  For the LTNP cohort, 
in which PBMCs were frozen before assessment, a response of ≥100 SFU/10 6 PBMC above 
background was regarded as positive as previously determined by Liebenberg (2007).  Using 
the ELISPOT results from a chronically HIV-infected woman shown in Figure 2.4, Table 2.4 
demonstrates how SFUs/106 cells were calculated from spots generated by the automatic 
scanner. 
 
2.14 Confirmatory ELISPOT of individual Gag and Nef peptide 
specificities 
Although the Gag and Nef peptide pool–matrix approach (Figure 2.4) to mapping individual 
HIV specificities identifies putative individual peptide specificities, it was necessary to 
confirm these specificities using a subsequent ELISPOT in which the individual peptides 
identified in the screen were included.  Each peptide pool with a positive response (defined in 
section 2.13) was matched with each matrix with a positive response resulting in the 
identification of the putative individual peptide/s.  This is illustrated in Figure 2.5.  Once the 
potential reactive peptides were identified in this way, individual peptides matching the ones 
identified were confirmed by a subsequent ELISPOT.  For confirmatory ELISPOTS, 















Table 2.4 Method used to calculate SFU/106 cells in responses to HIV Gag and Nef pools and 
matrices from the ELISPOT experiment shown in Figure 2.4. 
 
 
    Spot no SFU/106  Cells     Spot no SFU/106  Cells 
  BG 0           
Gag POOL 1 19 190 Nef POOL 1 0 0 
  POOL 2 11 110   POOL 2 51 510 
  POOL 3 0 0   POOL 3 35 350 
  POOL 4 94 940   POOL 4 83 830 
  POOL 5 6 60   POOL 5 1 10 
                
Gag MATRIX 1 0 0 Nef MATRIX 1 72 720 
  MATRIX 2 0 0   MATRIX 2 28 280 
  MATRIX 3 0 0   MATRIX 3 44 440 
  MATRIX 4 21 210   MATRIX 4 28 280 
  MATRIX 5 16 160   MATRIX 5 0 0 
  MATRIX 6 0 0   MATRIX 6 0 0 
  MATRIX 7 0 0   MATRIX 7 1 10 
  MATRIX 8 25 250   MATRIX 8 0 0 
  MATRIX 9 12 120   MATRIX 9 8 80 
  MATRIX 10 0 0   MATRIX 10 35 350 
  MATRIX 11 1 10         
  MATRIX 12 1 10   PHA 492 4920 
  MATRIX 13 0 0   PHA 444 4440 
  MATRIX 14 0 0   PHA 417 4170 
  MATRIX 15 0 0         
  MATRIX 16 0 0   CEF(1425) 59 590 
  MATRIX 17 2 20   CEF(1425) 61 610 
  MATRIX 18 25 250   CEF(1425) 66 660 
  MATRIX 19 80 800         
  MATRIX 20 7 70         
  MATRIX 21 1 10         
  MATRIX 22-33 0 0         
 
 
The background response was 0.  Background SFU were subtracted from each stimulation condition 
and then multiplied by 10 (since 105 cells were plated/well while SFUs are expressed per 106 cells). 
For this chronically HIV infected women, a positive HIV-specific response was considered to be any 
response ≥ 100 SFU/106 and these are highlighted in blue and green.  Donor WP 1425 was used as the 
quality control PBMC sample included on every ELISPOT experiment performed.  CEF responses 
(yellow) by donor WP 1425 had to be within the range of 337-776 SFU/106 cells (detailed in appendix 
1) and PHA(yellow) responses > 500 SFU/106 (Streeck et al., 2009) cells for an experiment to be 


















                                
1 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 
P1 1 2 3 4 5 6 7 8 9 10 
P2 11 12 13 14 15 16 17 18 19 20 
P3 21 22 23 24 25 26 27 28 29 30 
P4 31 32 33 34 35 36 37 38 39 40 
P5 41 42 43 44 45 46 47 48 49 50 
 
 
Figure 2.5 Method used to identify two putative individual peptides detected in the chronically 
HIV-1 infected sample from positive responses in distinct pools and matrices.  The combination 
of a positive response to NEF pool 2 and matrix 3 would predict that the individual Nef peptide 13 
was being recognized.  The combination of Nef pool 4 and matrix 10 would predict that the individual 
Nef peptide 40 was being recognized. 
 
 
Positive responses may be detected in adjacent overlapping peptides therefore, when 
consecutive peptides were positive on the pool/matrix screening ELISPOT, only the higher of 
the two responses was considered positive.  In the case of three consecutive peptides being 
positive, the highest two responses were considered positive.  
 
2.15 Quality controls included on each ELISPOT plate  
The ELISPOT assay is a robust, reliable and reproducible way to detect IFN-γ T cell 
responses (Gray et al., 2009).  It is, however, important to include quality control measures to 
ensure that consistency is maintained throughout the study and across plates.  In this study, 
CEF peptides and PHA were used as positive controls; while medium alone and medium with 
cells were used as negative controls (as represented in Figure 2.4).  IFN-γ responses 
generated from negative control wells were never >30 SFU/106 PBMC.  While PHA was 
used to test the maximum ability of PBMCs to produce IFN-γ, CEF peptides served as a 
positive viral antigen control.  In addition, on each plate, PBMCs derived from a donor with 
well characterized responses to CEF peptides were included as a quality control for interplate 
and inter assay variability.  CEF quality control PBMCs were used on each ELISPOT plate 
included in this study and the details of this approach are detailed in Appendix 1. 













2.16 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5 (San Diego California USA). 
Mann-Whitney U test and the Wilcoxon Ranks Test were applied for matched and non-
matched non-parametric comparisons, respectively.  The Spearman Ranks and Pearson 
correlation were applied for testing correlations between non-parametric and parametric data 
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3.1 Clinical characteristics of acutely HIV-infected individuals  
Of the 500 HIV negative individuals recruited into this prospective observational sero-incidence 
study, 7 became infected with HIV during the 12 months of follow-up.  The schedule of evaluation 
for each of the seven individuals who became infected with HIV is shown in Table 3.1.  At 
enrollment (Table 3.2), the mean age of acutely infected individuals was 26 years (± 9 years; SD), 
they had a mean HIV viral load of 43004 RNA copies/ml (± 82174; SD), and a mean CD4 count of 
504 cells/µl (± 259; SD).  All 7 individuals who became infected with HIV during follow-up were 
female.  Acute HIV infection was considered to be the incident visit (mean of 21 days post infection; 
± 13 days) while 1-3 months post-infection was considered early infection and >6 months was 
considered to be chronic infection.  All the participants were confirmed by sequencing Gag to be 
infected with HIV-1 subtype C by Michelle Skelton in Prof Carolyn Williamson’s laboratory at the 
University of Cape Town (data not shown). 
Table 3.1 Monthly clinical visits of acutely (HIV-1 infected women 
Gender PID Incident M1 M2 M3 M6 M12 M18 M24 M30 
F C001                   
F C002                   
F B349                   
F B420                   
F C004                   
F C007                   
F C008                   
Green bars indicate the gender; yellow bars indicate their study number and blue bars, the clinical visits in months. 
 
Table 3.2 Clinical characteristics of women acutely infected with HIV 
PIDa Age  HIV-1 infection HIV-1 load CD4 count Duration of 
   at enrollment     follow up 
  (Years) (Days) (RNA copies/ml) ( cells/µl) (Months) 
C001 16 14 NAb 548 30 
C002 25 45 7480 548 4 
C004 37 36 11000 867 24 
C007 17 14 228000 177 3 
C008 21 15 16900 787 18 
B349 34 15 6400 305 0 
B420 34 11 31200 298 0 
Mean(SD) 26 ± 9 21 ± 13 43004 ± 82174 504 ± 259 11 ± 12 














CD4 counts during acute HIV infection were lower than those measured during early or chronic 
infection time points in women with longitudinal samples available although this was not significant 
(Figure 3.1A).  No significant difference was observed between plasma viral loads measured during 
acute, early and chronic phases of infection (Figure 3.1B).  Despite being recruited at 21 days post 
HIV-infection, this finding suggests that their acute phase peak viral load was already declining at 
the earliest time point (incident visit) at which their viral loads were measured.  There was, however, 
no association between time post-HIV infection (estimated time from infection to enrollment in days) 


















































Figure 3.1 Blood CD4 counts (A) and HIV RNA loads in plasma (B) in acutely HIV-infected women.  
Red spots represent acute (incident); green squares represent early infection (1-3 months); and blue triangles 
represent chronic infection (>6 months).  Mann-Whitney U tests were applied to compare these non-
parametric variables.  All data points reflect the CD4 counts and HIV RNA loads represented in tables A1 and 
















3.2 Relationship between CD4 T cell counts in blood and plasma viral load during 
acute HIV infection 
In acutely HIV-infected women over time, CD4 T cell counts were inversely associated with plasma 
viral load (Figure 3.2; Rho = -0.38; p=0.02).  Figure 3.3 shows the longitudinal relationship between 
plasma viral load and CD4 T cell counts in 5 of the 7 acutely HIV-infected women who were studied 
longitudinally.  Of the 5 women studied longitudinally, the clinical progression for 4 women (C001, 
C004, C002 and C007) showed CD4 T cell counts in blood declined during the course of infection 
while plasma viral loads generally increased over time (Figure 3.3).  In contrast, C008 showed no 
relationship between plasma viral load and CD4 T cell counts in blood.  
 




300000 Rho = -0.38
    p =  0.02

















Figure 3.2 Correlation between plasma HIV viral load (RNA copies/ml) and CD4 counts (cells/µl) 
during acute HIV-infection and over time.  Each dot represents the matched measurements of CD4 counts 
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Figure 3.3 Kinetics of CD4 T cell counts in blood (cells/µl) and HIV-1 viral load (RNA copies/ml) in 
women who became acutely infected with HIV.  HIV viral load is indicated by the green dots and CD4 
counts are indicated by blue squares.  Participant C001 was followed for 30 months, C002 for 4 months, C004 
for 24 months, C007 for 3 months and C008 for 18 months.  CD4 count and viral load measurements were 
taken monthly for the first 4 months, 3 monthly from 6 to 12 months and then 6 monthly thereafter. 








































3.3 Characterization of HIV-1 specific T cell responses during the acute phase of 
HIV infection 
The magnitude and breadth of HIV-1 Gag and Nef-specific T cell responses in acutely HIV-infected 
women were characterized by IFN-γ ELISPOT.  Five out of the seven (71%) acutely HIV-infected 
women had detectable Gag and/or Nef-specific T cell responses at enrollment (mean 21 days post 
infection) (Figure 3.4).  The magnitude of T cell responses directed against HIV subtype C Gag 
peptides ranged from 60 – 110 SFU/106 PBMC (Figure 3.4A) while responses directed against Nef 
peptides ranged from 170 – 1110 SFU/106 cells (Figure 3.4B).  Participant C001 was found to have 
the highest magnitude response to Gag (200 SFU/106 cells) that was directed against Gag pools 1 and 
5.  Participant B420 had the highest magnitude response to Nef (1110 SFU/106 cells) and was the 
only individual who responded to both Nef and Gag.  More acutely infected women targeted Gag but 















































































Figure 3.4 Magnitude of HIV-1 specific T cell responses to Gag and Nef peptides during acute infection. 
Histograms show all positive responses in SFU per million PBMC as determined by the cut off criteria (in 
method).  Graph A represents responses to Gag pools and B responses to Nef pools.  Gag pool 1 are peptides 
representing p17; pool 2, pool 3 and pool 4 the p24 and pool 5 the p15 regions of the HIV-1 Gag protein. 
















The breadth of HIV-specific T cell responses to Gag and Nef (characterized by the number of Gag or 
Nef pools targeted) was limited during acute HIV infection with only 2/7 individuals (C001 and 
B420) targeting more than 1 pool within either Gag or Nef.  Participant C001 targeted two Gag pools 
and B420 targeted 1 Gag and 1 Nef pool.  The remaining acutely infected women (C004, C007 and 
C008) targeted only a single pool within Gag or Nef.  There was a statistically significant correlation 
(Rho = 0.93; p = 0.02) between the number of Gag and/or Nef pools targeted and HIV viral load 
during the initial stage of disease (results not shown).  
The breadth of HIV Gag or Nef responses was further characterized by mapping individual peptide 
responses in each woman (Table 3.3).  Participant C001 targeted peptides Gag11 
[LERFALNPGLLETSE] and Gag99 [KEGHIARNCRAPRKK].  Participant B420 targeted Gag7 
[GKKHYMLKHIVWASR], Nef33 [PGPGVRYPLTFGWCF] and Nef34 [VRYPLTFGWCFKLVP].  The 
Nef RW8 epitope [RYPLTFGW], embedded in the Nef 34 peptide [VRYPLTFGWCFKLVP] was 
amongst those epitopes that were confirmed HIV subtype C epitopes from the Los Alamos database 
(http://www.hiv.lanl.gov/content/hiv-db/ELF/epitope_analyzer.html (accessed 15 December 2010) 
and matched previously described HIV-1 subtype B epitopes (Masemola et al., 2004).  
 
Table 3.3 Individual Gag and Nef peptide mapping during acute HIV infection 
PID Peptide Epitope location Magnitude Peptide Sequence 
HLA Class I 
 restriction 
   Number  (SFU/106 cells)     
C001 Gag 11 p17 110* LERFAVNPGLLETSE B63 
 Gag 99 p15 90* KEGHLARNCRAPRKK A3 
C004 Nef 19 central 410 QVPLRPMTYKAAFDL     B*3501 
C007 Gag 99 p15 50 KEGHIAKNCRAPRKK A*03 
C008 Gag 74 p24 140 YVDRFFKTLRAEQAT Cw*0303;B*1503 
B420 Gag 7 p17 120 GKKHYMLKHIVWASR A*2301 
 Nef 33 central 360 PGPGVRYPLTFGWCF     B*27 
  Nef 34 central 380 VRYPLTFGWCFKLVP     B*27 
*Unconfirmed individual peptide specificities.  Pool/matrix predicted peptides are included.  The underlined 
portion of the peptide represents the previously defined epitope as described in the Los Alamos database. 
  
The remaining peptides that were targeted by individuals C004, C007 and C008 were Nef19 
[QVPLRPMTYKAAFDL], Gag99 [KEGHIARNCRAPRKK], and Gag74 [YDVRFFKTLRAEQAT], 














[QVPLRPMTYKAAFDL], was previously described as an immunodominant epitope in acute 
infection (Streeck and Nixon, 2010).  Although the HLA types of these women were not determined 
in this study, this Nef VY8 epitope [VPLRPMTY] has previously been reported to be restricted by 
HLA B*35 and was found to be more likely to be recognized during acute infection than during 
chronic infection (Streeck and Nixon, 2010).  In this study, only 13% of Gag peptides that were 
targeted during acute HIV infection were located within the most conserved p24 region while the 
remaining Gag responses were equally located within the p17 and p15 region.  All the Nef peptides 
targeted were situated within the central most conserved region. 
 
3.4 Longitudinal mapping of HIV-specific T cell responses in acutely HIV 
infected women  
Following acute infection, HIV Gag- and Nef-specific T cell responses were characterized over time 
in 5/7 individuals for whom longitudinal samples were available.  Responses were followed until the 
chronic stages of HIV infection in 3 women (C001, C004 and C008) while responses were followed 
until early infection in 2 women (C002 and C007).  Generally, the total magnitude of T cell 
responses to Gag and Nef increased over time in all 3 women followed from acute HIV infection to 
chronic phases of infection (Figure 3.5).  T cell responses to Gag dominated the acute phase of 
infection, whilst responses to Nef were more prominent during the chronic stages of infection.  
During the first year of infection, the magnitude of Gag in participant C001 fluctuated between 57 
and 440 SFU/106 cells, reaching a plateau at 800 – 840 SFU/106 cells during 18-24 months post 
infection.  In contrast, the Nef response was higher than Gag responses (median 1180 SFU) but 
fluctuated between 444 and 2400 SFU/106 cells.  In comparison with C001, the magnitude of Gag 
responses in participant C004 remained low throughout 24 months of follow-up with the highest 
response being detected at 12 months (370 SFU/106 cells).  Nef responses in this woman steadily 
increased from 170 SFU/106 cells during acute HIV infection to 1260 SFU/106 cells by 24 months 
post-infection.  In participant C008, T cell responses to both Gag and Nef peaked at 6 months with 










































































Figure 3.5 Longitudinal HIV-specific T cell responses to Gag and Nef peptides in women who recently 
became infected with HIV.  All responses (SFU/million PBMC) that were determined to be positive were 
according to the cut off criteria.  Gag pool 1 are peptides representing p17 pool 2, pool 3 pool 4 the p24 and 
pool 5 the p15 regions of the HIV-1 Gag protein.  The Nef pools, 2, 3 and 4 represent the central conserved 




































The extent of expansion and contraction in the total magnitude of Gag and Nef-specific T cell 
responses were analyzed by assigning a variance score within individual response at each time point.  
The variance score was calculated by dividing the magnitude of IFN-γ responses (SFU/106 cells) 
measured at a particular time point by the average magnitude at all time points tested.  Longitudinal 
responses with a variance score approaching 1 would be indicative of a stable response over time of 
infection.  The variance score over time for the three (C001, C004 and C008) individuals were 




















Figure 3.6 Variance scores for Gag and Nef T cell responses measured over 24 months from acute HIV 
infection in three women with samples available.  Participant C001 is shown in dark blue, participant C004 
is shown in medium blue, and C008 is shown in light blue.  The variance scores were determined by dividing 
the magnitude to Gag and Nef (SFU/106 cells) generated at a particular time point by the average magnitude at 
all time points tested.  A score approaching 1 means low deviation. 
 
3.5 Clinical characteristics of HIV-infected long-term non-progressors  
Nine women who had been infected with HIV for >5 years and maintained CD4 counts >300 cell/ul 
in the absence of HAART were included in this study to compare immune responses measurable in 














LTNPs were studied longitudinally at 3-4 consecutive 6 monthly visits and details of the visits 
included in this study are summarized in Table 3.4.  They had been infected for a mean 2352 days or 
6.5 years (±412 days; SD) and continued to be naïve to HAART at the time of study (Table 3.5).  
The mean age of the LTNPs was 35 years (±6 years), and they had a mean HIV viral load of 10170 
(±16943; SD) copies per ml.   
Table 3.4 Six monthly clinical visits of LTNPs 
Gender PID M66 M72 M78 M84 M90 M96 M102 M108 M114 M120 M132 
F NY10                       
F NY40                       
F NY64                       
F NY94                       
F NY99                       
F NY100                       
F NY219                       
F NY234                       
F NY292                       
Green bars indicate gender, yellow bars the study number and blue bars the visits in months 
 
Table 3.5 Clinical characteristics of LTNPs 
PIDa Age  HIV-1 infection HIV-1 load CD4 count Duration of 
   at enrollment     follow up 
  (Years) (Days) (RNA copies/ml) ( cells/µl) (Months) 
NY010 41 1825 <50 334 24 
NY040 41 2373 7200 322 24 
NY064 27 2555 930 383 18 
NY094 38 2190 1700 465 24 
NY099 26 2008 10000 525 36 
NY100 33 2373 53000 778 6 
NY219 33 2373 16000 551 12 
NY234 35 2190 2600 680 24 
NY292 42 3285 <50 529 24 
Mean(SD) 35 ± 6 2352 ± 412 10170 ± 16943 507 ± 153 21 ± 8 
 
Unlike the women who were acutely infected with HIV, an inverse relationship was not observed 
between plasma viral load and CD4 counts in the nine LTNPs (Rho= 0.12; p=0.47).  Although no 
relationship was found when all LTNPs were grouped together, four of these nine women (NY040, 














viral load at an individual level while the remaining women (NY010, NY094, NY100, NY234 and 
NY294) showed no relationship (Figure 3.7 and Figure 3.9).  Furthermore, there were no significant 
differences between longitudinal CD4 counts and HIV-1 plasma viral loads (Figure 3.8A and B). 




300000  Rho = 0.12
     p = 0.47
CD4 Count (cells /µl)
 
Figure 3.7 Relationship between plasma HIV viral load (RNA copies/ml) and CD4 counts (cells/µl) in 
HIV-1 infected LTNPs.  Each dot represents the matched measurements of CD4 counts and viral load of nine 
participants longitudinally.  Spearman Ranks test for correlation was used to calculate the Rho and p values 













































Figure 3.8 Blood HIV-I RNA load (A) and CD4 T cell counts (B) in HIV-infected LTNPs.  Red dots 
represent 66+ months post infection; green squares represent 84+ months post infection; and blue triangles 















































































































































































Figure 3.9 Kinetics of CD4 T cell counts (cells/µl) and HIV viral load (RNA copies/ml) in LTNPs 
(NY010, NY040, NY064, NY094, NY099, NY100, NY219, NY234, NY094 and NY292) who have been 
chronically infected with HIV for >5 years.  HIV viral load is indicated by the green dots and CD4 counts are 











































3.6 Characterization of HIV-specific T cell responses in LTNPs over time  
Nine LTNPs women who had been infected for >5 years (without initiation of HAART) were 
followed longitudinally to determine the fluidity of T cell responses to HIV Gag peptides during 



























































































































Figure 3.10 Longitudinal evaluations of HIV-1 specific T cell responses to Gag Du422 peptides in HIV-
infected LTNPs (NY040, NY100, NY 219, NY234, NY064, NY 099, NY010, NY094, and NY292).  Gag 
pool 1 (red bars) represent peptides contained in p17 of Gag; pool 2 (blue bars), pool 3 (green bars) and pool 4 
(purple bars) contained peptides in p24 of Gag; while pool 5 (yellow bars) contained peptides in p15 regions 
of the HIV-1 Gag protein. 
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Generally, the magnitude of Gag-specific T cell responses in these HIV LTNPs was higher than 
those detected in women who were acutely infected with HIV.  Furthermore, the Gag pools targeted 
and the magnitude of responses to each pool was less variable in these HIV LTNPs over time than in 
acutely infected women.  NY292 had the highest T cell responses to Gag (ranging from 6520 to 
18160 SFU/106 cells).  NY040 had the lowest T cell responses to Gag (ranging from 1326 to 1586 
SFU/106 cells).  Although these HIV LTNPs tended to have less variation in their overall magnitude 
of Gag-responses over time than women during acute infection, the response magnitude and pools 
targeted remained relatively constant in 2/9 women (NY040 and NY099), declined over time in 4/9 
women (NY064, NY094, NY234 and NY219) and increased with time in 3/9 women (NY010, 
NY100 and NY292). 
Variance scores were calculated in the 5/9 long-term chronically HIV-infected individuals who had 
at least three visits available for analysis.  In contrast to the acutely HIV-infected women (Figure 
3.6), Figure 3.11 shows that all 5 of these LTNPs had variance scores close to 1 over 18 months of 




















Figure 3.11 Variance scores of five HIV-infected LTNPs.  These five women (NY010, NY094, NY099, 
NY040 and NY219) all had three longitudinal time points available for analysis.  The variance scores were 
determined by dividing the magnitude of Gag (SFU/106 cells) generated at a particular time point by the 














3.7 Contribution of Gag and Nef responses to the overall magnitude of HIV-
specific T cell responses during acute versus chronic infection  
During acute HIV infection, HIV-specific T cell responses targeted the three proteins of Gag in 
almost equal proportions, with 38% of responses detected against p17, 32% against p24 and 30% 
against p15 (Figure 3.12A).  During early HIV infection, only two regions of Gag were targeted (p24 
and p17) with 58% of responses targeting p17 and 42% targeting p24.  In the same women during the 
chronic phase of HIV-1 infection, p24 and p17 emerged as the co-dominant regions being targeted 
within Gag and these accounted for 44% and 47% of the total Gag-specific T cell responses 
measured, respectively.  Although p24 (the most conserved region of the Gag protein) showed no 
outright dominance throughout the coursee of infection, it was the only region that steadily increased 
in the proportion it was targeted [accounting for 32% of responses during acute infection, 42% of 
responses during early infection, and 44% of responses during chronic infection).  In contrast, p15 
was the most variably targeted region of Gag [accounting for 30% of responses during acute 
infection, none of the responses during early infection, and 9% of responses during chronic 
infection].  In this study, the p24 region of Gag was made up by Gag peptide pool 2, pool 3 and pool 
4.  Within these three Gag p24 peptide pools, the end of p24 (pool 4) accounted for the largest 
proportion of responses (32%) in acutely HIV-infected women and remained the most targeted of 
p24 regions throughout the course of HIV infection in these women.  
In Nef, T cell responses targeting the central most conserved region of this protein (made up of pool 
2, pool 3 and pool 4) consistently were the most targeted throughout the course of HIV-1 infection 
(Figure 3.12B).  Nef pools 2 and 4 contributed 13% and 87% respectively during acute HIV 
infection.  During early HIV infection, Nef-specific targeting shifted from pool 4 to pool 2 
contributing 53% of the overall Nef responses.  During chronic infection in these women, pool 2 
emerged as the most dominant Nef pool targeted (accounting for 80% of responses to Nef).  
Although targeting of the central region of Nef accounted for most of the T cell responses detected 
against this protein, the exact pools targeted within this central region were highly variable 
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Figure 3.12 Relative contribution of each Gag (A) and Nef (B) peptide pool to the overall magnitude of 
the T cell responses to each HIV protein over time from acute to chronic HIV infection.  The magnitudes 
are expressed as percentage in seven acutely, 4 early and 3 chronic chronically infected women.  (A) Red 
slices represent Gag p17.  Blue, green and purple slices represent pools 2, 3 and 4 of Gag p24.  Yellow slices 
represent p15 of Gag.  (B) Blue, green and purple slices represent pools 2, 3 and 4 of Nef (central) and the 



































Figure 3.13 Relative contribution of each Gag pool to the overall magnitude of the T cell responses over 
time in nine LTNPs.  Red slices represent Gag p17.  Blue, green and purple slices represent pools 2, 3 and 4 
of Gag p24, and yellow slices represent Gag p15.  The first time point is at 66+ months, the second, 84+ months 














In HIV-infected LTNPs, T cell responses to p24 contributed 88% of all Gag responses at 66 months 
of infection, 79% at 84 months and 92% at 96 months post-infection (Figure 3.13).  In contrast, 
responses to p15 and p17 of Gag made up less than a quarter of total Gag responses throughout the 
course of infection.  When the proportionate contribution of each Gag region targeted by T cells 
(Figure 3.12 and Figure 3.13) wasadjusted for the number of amino acids in each region of Gag (by 
dividing the magnitude of T cell response by the number of amino acid within that protein to 
compensate for the fact that p24 was so much longer than p15 or p17), there were slight differences 
between before and after normalization in LTNPs, although p24 still remained the highest contributor 
to the overall Gag specific response (Figure 3.14). 
 
 
Figure 3.14 Adjustment of Gag-specific T cell responses to compensate for varying lengths of Gag 
regions in nine HIV-infected LTNPs.  The comparisons between normalized (column A) and non- 
normalized (column B) Gag specific T cell responses to the overall magnitude at 84 months+ and 96 months+ 
post infection.  The magnitude of response to each protein was divided by the number of amino acids within 















3.8 Identification of specific Gag and Nef peptides targeted by HIV-specific T cell 
responses during the natural course of HIV infection 
Individual peptide mapping was carried out longitudinally in 3/7 acutely HIV-infected women 
(C001, C004 and C008) to investigate how specific HIV regions were being targeted evolved during 
the course of infection.  C001 had returned for eight clinic visits while C004 and C008 had returned 
for six clinic visits each.  Initially, only a few Gag and Nef peptides were recognized during acute 
HIV infection indicating the breadth of responses was initially narrow but the number of peptides 
recognized increased over time of infection (Figures 3.15).  A total of 94 distinct peptides were 
identified in Gag and Nef.  Of these, 23/94 peptides (24%) were recognized during acute infection, 
30/94 peptides (32%) were recognized during early infection, and 41/94 peptides (44%) were 
recognized during chronic infection.  Participant C001 recognized the greatest number of these 94 
peptides (46/94 individual peptides), followed by C004 (23/94 individual peptides), and C008 
recognized 19/94 peptides.  The number of peptides targeted varied at different time points in all 
three participants; with C001 recognizing the most peptides at month 24 (14 peptides being 
recognized), C004 peaked at month 12 (7 peptides being recognized) and C008 peaked at month 6 (6 
peptides being recognized). 
 
In some women, IFN-γ responses to the individual peptides were conserved longitudinally (Figure 
3.15).  The most conserved peptide recognized in C001 was Gag 11 with 6/8 time points targeting 
this peptide (Figure 3.15A).  The most conserved peptide recognized in C004 was Nef 19 with 
samples from 6/6 time points targeting this peptide (Figure 3.15B).  In C008, both Gag peptide 19 
and Nef peptide 19 were recognized simultaneously at 4/6 time points (Figure 3.15C).  In contrast, 
recognition of other peptides was more fluid.  In C001, Nef 21 was only recognized during chronic 
infection and not during acute infection.  In C008, Gag peptides 74 and 88 were only recognized 

















 A            
C001 Peptide     Day0 Mo1 Mo3 Mo6 Mo12 Mo18 Mo24 Mo30 
  Gag3      60 960 600 70     
  Gag4              140   
p17 Gag9            50     
  Gag11   110*   130 60 320   90 120 
  Gag17               60 56 
  Gag20             60 270 140 60 
  Gag35             50   180 
  Gag47                 80   
  Gag60     57*         60   
p24 Gag66             70 120   
  Gag69                 60   
  Gag76                 420 
  Gag80         50 50     270   
p15 Gag97             50     
  Gag99     90*       230 120 150 150 
                    
  Nef11                 90   
  Nef20           140   170 340 600 
Central Nef21         300 340 850 
  Nef30                 140   
C-terminal Nef47                   160 
              
Number of peptides   2 1 3 4 4 9 14 9 
 
B               
COO4 Peptide   Day0 Mo3 Mo6 Mo12 Mo18 Mo24 
  Gag5    230 60 50     
p17 Gag6      405      
  Gag13        180     
  Gag16       60     150   
  Gag34    50        
  Gag35        100     
p24 Gag38       60 130 260     
  Gag54        180     
  Gag62        120     
  Gag64             130 130 
                    
Central Nef16           110 
  Nef19     410 260 180 100 650 1390 
          
Number of peptides   1 5 4 7 3 3 
 
















C           
C008                   Peptide   Day0 Mo1 Mo3 Mo6 Mo12 Mo18 
  Gag17           310 240   
p17 Gag19      140 1170 120 285 
  Gag20         60 60     
  Gag74    140           
p24 Gag76         470 90 345 
  Gag88         100       
                    
Central Nef19         220 840 360 835 
  Nef30           240 100   
          
Number of peptides  1 0 4 6 5 3 
 
Figures 3.15 Mapping of HIV-specific Gag and Nef peptides targeted longitudinally in three women 
over a period of 18-30 months following acute infection.  The HIV-1 proteins are Gag p17 (red), p24 (dark 
purple) and p15 (yellow) and the Nef protein constitute the central conserved (dark purple) and C terminal 
regions (yellow).  The peptide columns represent the peptide recognized by Nef or Gag specific T cell 
responses.  Each colored square going across represents the breadth of the recognized peptide at a particular 
time point.  The color of the square represents the pool in which the peptide is situated; peptides recognized 
within Gag or Nef: - pool 1(red); pool 2(blue); pool 3(green); pool 4 (purple) and pool 5 (yellow).  The 
number within the square represents the longitudinal (magnitude of response in SFU per million PBMC) 
responses of the recognized peptide over time.  The greatest number of peptides targeted is circled in blue. 
 
Figure 3.16 summarizes the overall proportion of peptides targeted from acute to chronic HIV 
infection in Gag and Nef.  During acute infection, almost equal numbers of Gag peptides within the 
p15 and p17 regions were recognized.  During early infection there was a shift in peptide recognition 
with equal peptide clustered in p24 and p17.  During the chronic HIV infection, peptides were 
recognized within all three regions although p15 peptides were less well recognized than both p17 
and p24 peptides.  The number of peptides recognized within p15 was lowest during early and 
chronic infection.  In Nef, the highest number of peptides recognized was in the central part of Nef 





















































































Figure 3.16 Summary of the frequency of peptide recognition within Gag (A) and Nef (B) from acute to 
the chronic HIV-1 infection.  The overall number of peptides recognized is expressed as percentage in seven 
acutely, 4 early and 3 chronic chronically infected women.  The red bars represent the peptides recognized in 
p17, purple p24 and yellow p15 of Gag. Peptides recognized within Nef; purple bars, central and yellow bars, 
C- terminal. 
 
The breadth of Gag-specific T cell responses in the 9 LTNPs is shown in Figure 3.17.  These LTNPs 
targeted a total of 121 individual peptides in Gag during follow-up.  Of these 121 individual peptides, 
20/121 peptides (17%) were from the p17 region of Gag, 82/121 peptides (67%) were from p24, and 
19/121 (16%) were within the p15 region of Gag.  In these chronically infected LTNPs, the number 
and identity of each peptide remained relatively constant over time with one exception.  While 
participant NY292 targeted only 5 peptides at 108 months post-infection, the breadth of her 
responses increased steadily to 13 peptides being recognized at 132 months post-infection.  Gag p24 
was consistently the most targeted region with 61% of the peptides being recognized in this region at 
66 months; 59% of the peptides being recognized at 84 months; and 77% of the peptides being 























p24 Gag35   165   370 
 Gag45   3925 5077 6890 
p15 Gag93   425   120 
Number of  
peptides   3 1 3 
 
 
NY 40 Peptides  Mo84 Mo90 Mo108 
 Gag73   730 960 1370 
p24 Gag74   600 580 900 
 Gag83     130 











NY 64 Peptides   Mo84 Mo94 Mo96 Mo102 
p17 Gag6   720 660 660 667 
  Gag73   1770 1810 3160 2677 
p24 Gag83   1430 2250 2140 2567 
  Gag87   230 150 120 167 
p15 Gag105    140 500  
  Gag106   970   1897 
Number of 
peptides   5 5 5 5 
 
       
NY94 Peptides  Mo72 Mo78 Mo90 
  Gag8   153 190 340 
p17 Gag10   153 320 140 
 Gag20   183 300 600 
 Gag36   623 860 1360 
p24 Gag73   313 340 260 
 Gag87   2553 1950 4500 
 Gag88   3633 3170 5340 
p15 Gag106   313 510  
  Gag107   443  700 
Number of 
peptides   9 8 8 
 
      
NY99 Peptides  Mo72 Mo78 Mo96 
  Gag34   160 240 895 
p24 Gag40   3807 3320 3815 
  Gag73   640 880 1425 
Number of 

















NY 100 Peptides  Mo90 Mo96 
  Gag8   1217 1300 
p17 Gag14   277  
 Gag40   937 860 
p24 Gag74   237  
p15 Gag106    200 
Number of 
peptides   4 3 
 
NY 219 Peptides  Mo66 Mo72 Mo78 
p17 Gag20   1235 350 330 
 Gag36   2035 410 1070 
p24 Gag69   1245   
Number of 
peptides   3 2 2 
 
NY 234 Peptides  Mo72 Mo90 
p24 Gag65   1040 620 
p15 Gag105   800  
Number of 
peptides   2 1 
 
NY 292 Peptides   Mo108 Mo114 Mo120 Mo132 
p17 Gag4        210 
 Gag35     113  667  
 Gag42        120 
 Gag44     1523 713 5067 5430 
 Gag45     1553 1053 4087 5360 
 Gag53      110 
p24 Gag62     513 313 2687 2720 
 Gag67      173 667 890 
 Gag72     113 135 394 4420 
 Gag73      713 3687 4290 
 Gag75        150 
 Gag83        150 
p15 Gag93       137 240 
 Gag111       387 480 
Number of 
peptides    5 6 9 13 
 
 
        
Figures 3.17 Mapping of HIV-specific Gag peptides targeted longitudinally in nine LTNPs that were 
studied longitudinally.  The peptide columns represent the Gag peptides recognized: Gag p17 (red), p24 
(dark purple) and p15 (yellow).  Each colored square going across represents the breadth of the recognized 
peptide at a particular time point.  The color of the square represents the pool in which the peptide is situated; 
peptides recognized within Gag: - pool 1(red); pool 2(blue); pool 3(green); pool 4 (purple) and pool 5 
(yellow).  The number within the square represents the longitudinal (magnitude of response in SFU per 

























































Figure 3.18 Summary of the frequency of peptide recognition within Gag in nine HIV- LTNP infected 
women.  The overall number of peptides recognized is expressed as percentage at 66 months+, 84 months+ 
and 96 months+ post infection.  The red bars represent the peptides recognized in p17, purple p24 and yellow 
p15 of Gag. 
 
3.9 Relationship between magnitude and breadth of T cell responses and HIV 
clinical status during acute versus chronic HIV infection 
The relationship between HIV clinical status (CD4 T cell counts and plasma viral loads) and the 
magnitude of T cell responses to Gag peptides was investigated during both acute and chronic HIV 
infection (Figure 3.19).  An inverse relationship was observed between the magnitude of T cell 
responses to Gag and plasma viral load following acute HIV infection although this was not 
significant (Figure 3.19A; Rho=-0.24; p=0.2).  A significant negative association was found between 
the overall magnitude of T cell responses to Gag (and specifically the p24 region) and plasma viral 
load in the 9 LTNPs (Figure 3.19C: Rho=-0.59; p=0.001 for whole of Gag; Figure 3.19D: Rho=-




















800000.0 rho = -0.2399
  p = 0.2281























150000 rho = 0.2601
   p = 0.2822























60000 rho = - 0.5896
   p = 0.0012























60000  rho = - 0.6696
   p = 0.0001























Figures 3.19 Relationship between plasma viral load and T cell responses to Gag and p24 in women 
acutely infected with HIV (A-B) compared to LTNPs (C-D).  A and B: Each dot represents matched 
measurements of HIV viral load (RNA copies/ml) and the magnitude (SFU/106PBMC) following acute 
infection.  C and D: Each dot represents matched measurements of HIV viral load (RNA copies/ml) and the 
magnitude (SFU/106 PBMC) during long-term chronic infection.  Spearman correlations were used and p 



















When the impact of the HIV clinical status on the breadth of T cell responses to Gag and Nef was 
assessed, no correlation was observed between the breadth of responses to Gag or Nef and plasma 
viral load in both the acute and LTNP cohorts (Rho=-0.11; p=0.64 for acute women; Rho=-0.29; 
p=0.14 for long-term chronic women; results not shown).  Although I did not observe an association 
between breadth of responses and clinical status, a significant positive correlation was found between 
the overall magnitude of T cell responses to Gag and/or Nef and the breadth of responses in both 
acutely (Rho=0.78; p<0.0001) and LTNP infected women (Rho = 0.68; p=0.0001; Figures 3.20). 
 
 




15  rh0 = 0.7803
      p = <0.0001

















15 rho = 0.6749
   p = 0.0001











Figures 3.20 Relationship between overall magnitude of T cell responses to Gag or Nef and the number 
of peptides being recognized in acutely infected women and LTNPs.  A: Each dot represents the matched 
measurements of magnitude (SFU/106 PBMC) and breadth of the total HIV-Gag and Nef specific T cell 
responses following acute infection.  B: Each dot represents the matched measurements of magnitude 
(SFU/106 PBMC) and breadth of the total HIV-Gag specific T cell responses in LTNP infected women.  



















3.10 Relationship between immunodominant responses to Gag or Nef in the 
control of HIV infection 
Table 3.6 summarizes the individual peptides targeted during acute HIV infection in the three women 
who were followed longitudinally that were characterized in this study as being immunodominant.  
Immunodominance was determined based on the fact that these individual peptides yielded the 
highest magnitude responses by ELISPOT in each woman.  During the acute phase of infection in 
participant C001, Gag 11 [LERFALNPGLLETSE] from p17 was the immunodominant peptide 
recognized and remained immunodominant during early infection.  In participant C008, Gag 74 
[YVDRFFKTLRAEQAT] was identified as the immunodominant peptide response.  In participants C004 
and C008, Nef 19 [QVPLRPMTYKAAFDL] from the central conserved region of Nef was the 
immunodominant peptide recognized.  In participant C004, this Nef peptide remained the 
immunodominant peptide recognized in early infection.  During chronic HIV infection, there was a 
shift in the immunodominance patterns in two participants (C001 and C008).  The immunodominant 
peptide recognized in participant C001 shifted from Gag 11 [LERFALNPGLLETSE] recognized during 
acute infection to Gag 3 [RGEKLDKWEKIRLRP] during the chronic phase of infection, although these 
peptides were both within the p17 region of Gag.  The only peptide targeted in acute infection in 
C008, was Gag 74.  The response then shifted to Nef 19 [QVPLRPMTYKAAFDL] and Gag 19 
[EELKSLYNTVATLYC] in early and chronic infection. 
Generally, the immunodominance patterns in LTNPs was maintained longitudinally with 89% of the 
peptides recognized within the p24 region and 11% of the peptides recognized in the p17 region 
(Table 3.6). Participant NY100 recognized peptide Gag 8 [YMLKHIVWASRELER] that is situated in 
the p17 region of Gag while the remaining participants targeted the p24 region.  NY010 and NY292 
both recognized Gag 45 [TPQDLNTMLNTVGGH] while NY040 and NY064 recognized Gag 73 
[GPKEPFRDYVDRFFK].  NY219 recognized peptide Gag 36 [HQAISPRTLNAWVKV], NY099 
recognized Gag 40 [EEKAFSPEVIPMFTA], NY234 recognized Gag 65 [DIYKRWIILGLNKIV], and 

















Table 3.6 Immunodominant epitope and HLA predictions. 
PID Phase Peptide  Region Sequence HLA ClassI 
C001 Acute Gag11 p17 LERFAVNPGLLETSE B*27 
    LERFAVNPGLLETSE B*63 
C004  Nef 19 Central QVPLRPMTYKAAFDL     B*27,A*11,A*3,A*35 
    QVPLRPMTYKAAFDL     B*35,B*42 
C008    Gag 74  p24  YVDRFFKTLRAEQAT  B*15.A*26,B*70 
C001 Early Gag11 p17   
C004; C008  Nef 19 Central   
            
C001 Chronic Gag 3 p17 SGGEKLDRWEKIRLRP B*44,B*60 
    RGELDRWEKIRLRP B*4002; B*40 
    RGEELDRWEKIRLRP B*63 
C004  Nef 19 Central   
 
C008    Gag 19   p17 EELKSLYNTVATLYC A*02 
NY100 LTNP Gag8 p17 YMLKHIVWASRELER A*11 
NY219  Gag36 p24 HQAISPRTLNAWVKV B*57;B*5801 
NY99  Gag40 p24 EEKAFSPEVIPMFTA B*4501 
    EEKAFSPEVIPMFTA B*57 
    EEKAFSPEVIPMFTA B*57;B*5801 
NY10; NY292  Gag45 p24 TPQDLNTMLNTVGGH B*0702;B*4201; 
NY234  Gag65 p24 DIYKRWIILGLNKIV B*0801 
    DIYKRWIILGLNKIV B*27 
NY40; NY64  Gag73 p24 PFRDYVDRFFKTLRA Cw *18 
    PFRDYVDRFFKTLRA A*24 
NY94  Gag88 p24 GVGGPGHKARVLAEA B*7 
            
The underlined portion of the peptide represents the previously defined epitope as described in the Los 




The HLA typing of the women in this study was not available.  However, some of these 
immunodominant peptides recognized contained well-characterized epitopes (Table 3.6).  Participant 
C004 recognized peptide Nef 19 which contains the epitope VPLRPMTY (VY8).  VY8 has 
previously been reported to be an HLA-B*35 restricted epitope and it is present in about 20% South 
Africans with HIV-1 subtype C infection (Kiepiela et al., 2004). VY8 was also found to be 














the finding of this study.  Participant C008 recognized peptide Gag 19 in p17 that contains the 9 
amino acid epitope SLYNTVATL (SL9).  SL9 has previously been defined as an A*02 restrictive 
epitope and the likely hood of being targeted by specific T cells during chronic infection is 20% 
higher than being targeted during acute infection (Goulder et al., 2001; Streeck and Nixon, 2010).  
NY234, a LTNP, recognized peptide Gag 65 in p24 that contains the epitope KRWIILGLNK (KK10).  
KK10 is a well known HLA-B*27 restricted epitope and was found to be a rare HLA allele 
expressed in South Africans with HIV-1 subtype C infection (Kiepiela et al., 2004).  T cells 
recognizing KK10 are more commonly detected during acute infection and this specificity is 
associated with immune control (Streeck and Nixon, 2010).  In this study, however, it was found to 
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More than a decade has passed since the first studies described the temporal association between 
HIV-1 specific T cell responses and decreases in viremia during acute infection, suggesting the 
crucial role for T cells in the initial control of viral replication (Koup et al., 1994; Borrow et al., 
1994; Schmitz et al., 1999; Jin et al., 1999).  Subsequent studies have shown that CTLs can 
inhibit viral replication in LTNPs (Betts et al., 2006) and that effective pressure exerted by CTLs 
can cause HIV to rapidly escape by mutation during acute (Goonetilleke et al., 2009) and chronic 
infection (Draenert et al., 2004).  In South Africa, HIV-1 subtype C is the predominant subtype 
causing infection.  Knowledge of T cell responses during acute infection and their role in HIV-1 
subtype C pathogenesis will advance our understanding of the first immune responses behind 
immune control.  The aim of this study was to longitudinally map HIV-1 subtype C Gag and 
Nef-specific T cell responses by ELISPOT in recently infected women (mean 21 days ± 13) and 
compare these to LTNPs who had been infected for more than 5 years.  T cell responses to HIV 
Du422 Gag and Nef peptides were mapped at the single peptide level.  T cell responses to Gag 
and Nef during acute and chronic HIV infection were compared with markers of disease 
progression (plasma CD4 counts and HIV RNA load).   
Evolution of HIV-specific responses during acute infection and disease control 
During acute HIV infection, the breadth of HIV-specific T cell responses to both Gag and Nef 
peptide pools was narrower and responses were lower in magnitude compared to responses 
detected in the same women during chronic infection.  More women had detectable HIV Gag 
responses during acute infection than Nef although responses to Nef were generally higher in 
magnitude.  The kinetics of these HIV Gag and Nef specific T cell responses during acute 
infection and immunodominant peptides recognized did not remain static over time but 
fluctuated during the first months of infection.  Although T cell specificities and response 
magnitudes during acute HIV infection were fluid as previously described by Mlotshwa et al. 
(2010), the magnitude of HIV-specific responses were significantly associated with the breadth 
of responses. 
In women who were acutely infected with HIV, blood CD4 T cell counts were inversely 
associated with plasma HIV-1 RNA loads confirming that women with higher viral loads 













replicates rapidly and spreads throughout the body especially in the GALT, which are densely 
populated with CD4 CCR5 memory T cells (Brenchley et al., 2004; Picker et al., 2006).  
Approximately 80% of these CD4 T cells are depleted following 3 weeks of infection (Brenchley 
et al., 2004).  In blood, there is an exponential increase in viremia during acute HIV infection 
which reaches a peak of ≥ 1 million RNA copies per ml which corresponds with a low CD4 
count at the time of the peak (Fiebig et al., 2003).  This is followed by a slower rate CD4 decline 
from about five to six months (Schacker et al., 1997).  In untreated individuals, viremia plateaus 
at about 6 -12 months and can remain stable for several months or years until progressive CD4 
loss results in the onset of AIDS (Centlivre et al., 2007).  Consistent with this study, other 
studies have shown that during primary HIV subtype C infection, the mean plasma RNA 
inversely correlated with mean CD4 count (Gray et al., 2005; Novitsky et al., 2009). 
Mlotshwa et al. (2010) recently investigated the pattern of HIV-specific T cell responses during 
acute and early infection in 53 individuals by IFNγ ELISPOT.  As early as 2-8 weeks post 
infection, 75% of acutely infected individuals recognized epitopes in Nef while 50% of 
individuals recognized epitopes in Gag.  Although this study included far fewer individuals, only 
27% of women recognized Nef during acute infection while 57% of women recognized Gag.  At 
6 months post infection, Mlotshwa et al. (2010) found 100% of individuals targeted Nef and 
60% of individuals targeted Gag.  In this study, all women targeted Gag and Nef by 6 months 
post infection.  Longitudinally, Mlotshwa et al. (2010) found that responses against Nef were the 
highest in magnitude compared with any other HIV protein and this study also found that Nef 
responses were generally of higher magnitude than responses against Gag.  Quality control T cell 
responses to CEF were measured in each experiment and included on each ELISPOT plate to 
control for plate-to-plate and assay-to-assay variation that would impact on the interpretation of 
the results from this study.  In the QC samples, CEF responses were found to fall within the 
established CV ranges with minimal fluctuation from the mean (Appendix 1 Figure A3).  This 
suggests that the longitudinal fluctuations observed in the magnitude of Gag and Nef specific T 
cells in this study were not due to plate or assay variation but reflected accurate trends in Gag 













Turnbull et al. (2009) analyzed longitudinal HIV-specific T cell responses in 21 acutely HIV-
infected individuals and showed that the HIV epitopes recognized were generally narrow during 
acute infection and broadened with disease progression which is in agreement with this and other 
studies (Altfeld et al., 2001; Lichterfeld et al., 2004; Gray et al., 2009; Mlotshwa et al., 2010).  
Similar to the findings presented in this study, Turnbull et al. (2009) demonstrated that the HIV 
epitopes recognized fluctuated over time, resulting in hierarchical shifts. 
Of the three acutely infected HIV women studied to chronic stages of infection, C001 have 
shown the slowest rate of disease progression with a mean viral load of 4860 RNA copies/ml 
from month 1 to month 18.  At month 24, however, her viral load increased four-fold to 20200 
RNA copies /ml.  At month 3, her only T cell response was directed at Gag 60 
[TSTLQEQIAWMTSNP] which is situated in p24 of Gag which contains the HLA-B57/58 TW10 
restricted epitope which is associated with slow progression (Goulder and Watkins, 2008).  After 
3 months, her response to this peptide [TSTLQEQIAWMTSNP] was lost although it did re-emerge 
at 18 months of infection.  While she lost this response relatively early, several studies have 
shown that a common escape mutation induced by this response is the T242N in 
[TSTLQEQIAWMTSNP] which is associated with a less fit virus (Kiepiela et al., 2007; Goulder 
and Watkins, 2008).  At month 24, despite recognizing the TW10 epitope 
[TSTLQEQIAWMTSNP] again, she failed to continue controlling her viral load and this could 
possibly be due to an increase in the breadth of her response to Nef, which may have dampened 
her ability to control viral replication.  Several studies have shown that targeting of Nef and Env 
is associated with increased viral loads (Masemola et al., 2004; Zuniga et al., 2006; Turnbull et 
al., 2009; Ferre et al., 2010) and this could account for the lack of viremic control in C004 and 
COO8 where Nef was predominantly targeted. 
Goonetilleke et al. (2009) showed that the first emerging T cell responses during acute infection 
rapidly select escape mutations whichcoincided with decline from peak viremia and it is likely 
that the loss and emergence of T cell responses to HIV proteins reported in this study may 
similarly reflect escape of HIV from T cell pressure exerted by immunodominant responses 













HIV-specific T cell responses in LTNP are comparatively stable over time 
In the nine LTNPs (infected for >5 years), the kinetics of Gag-specific T cell responses were 
generally higher, more stable and frequency of epitopic recognition were more conserved than 
measured in the acutely HIV-infected women.  IFN-γ responses in these individuals 
preferentially targeted the highly conserved p24 region of Gag.  While the magnitude of T cell 
responses to Gag (particularly the p24 region of Gag) in LTNPs was significantly inversely 
associated with plasma viral loads at the same time point; no similar correlation was observed in 
women who were acutely infected with HIV.  Generally, no association was observed between 
the breadth of HIV-specific T cell responses and plasma RNA viral loads in either acutely 
infected women or LTNPs.  Several studies have shown that targeting of Gag by HIV-specific T 
cells was protective.  In a previous study with a large cohort of 578 chronically infected 
participants, it was shown that individuals who targeted Gag controlled vireamia better than 
individuals who targeted Env (Kiepiela et al., 2007).  Masemola et al. (2004) showed, in a mixed 
cohort of recently and chronically infected individuals, that preferential targeting of Gag was 
associated with low viral load while targeting of Nef was associated with high viral load.  
Another study of recently infected individuals has shown that HIV-specific T cells targeting p24 
region of Gag were associated with immune control (Streeck et al., 2007). 
In contrast, no correlation was found between CD4 T cell counts and plasma viral loads in 
LTNPs suggesting that women who are controlling viraemia and maintaining CD4 counts do not 
exhibit the same relationship between viraemia and CD4 loss as those progressing normally.  
Cao et al. (1995) previously reported that only about 5% of untreated chronically infected 
individuals with stable CD4 counts above 500 cells /µl (LTNPs) are able to immunologically 
control infection for longer than 10 years.  A small subset (<1%) of these individuals, known as 
elite controllers, maintain a viral load of less than 50 RNA copies/ml (Madec et al., 2005; 
O’Connell et al., 2009) suggesting very slow or undetectable disease progression in these 
individuals.  This is in contrast to rapid progressors who eventually succumb to AIDS within 3-5 
years of infection (Poropatich and Sullivan, 2011).  A small percentage of LTNP (±7%) may 
eventually progress to AIDS due to opportunistic infections.  Similarly, about 7% of elite 
controllers may meet the clinical definition of AIDS, where individuals with less than 75 copies 













controllers did not correlate with maintenance of CD4 counts in blood (Poropatich and Sullivan, 
2011). 
All nine LTNPs in this study predominantly responded to Gag throughout the time points 
included in this study and generally maintained CD4 counts >350 cells/µl in the absence of 
HAART.  Their magnitude of Gag-specific T cell responses was generally higher, more stable 
and the individuals peptides recognized were more conserved than acutely infected women.  
Furthermore, T cell recognition of p24 contributed >75% to the overall magnitude of Gag 
throughout the study and there was a significant inverse correlation between magnitude and 
breadth of p24 and viral load. 
Five of the 9 LTNPs (56%) studied longitudinally recognized peptides which could harbor HLA-
B*57/B*58/B*27-restricted epitopes: IW9 (Gag 36; NY219 and NY94), KF11 (Gag 40; NY99 
and NY100) and KK10 (Gag 65; NY234) which have all previously been associated with LTNPs 
(Kaslow et al.; 1996; Migueles et al., 2000; Navis et al., 2007; Kiepiela et al., 2007; predicted 
from the Los Alamos Data base, http://www.hiv.lanl.gov/content/hiv-db/ELF/epitope 
analyzer.html; accessed 10 January 2011).  The LTNPs in this study that recognized these 
protective epitopes are likely to have these protective HLA alleles (although HLA typing was not 
performed) and also had higher CD4 counts (although not significantly) compared to those who 
did not recognize these protective epitopes.  All these findings suggest that targeting of Gag, 
especially the conserved p24 region, is a good correlate of protection against disease progression. 
Role of HLA in HIV disease progression 
Studies have shown the importance of certain HLA class I alleles, particularly HLA-B, in 
determining the rate of disease progression (Kiepiela et al., 2004).  HLA-B*57/B*58 is 
overrepresented in LTNPs and certain HLA-B alleles are shown to be beneficial and others to be 
disadvantageous to the host (Goulder and Watkins, 2008).  HLA-B57*/B*58 and B*27 are 
protective alleles whereas HLA-B*35 is associated with rapid disease progression.  A major 
limitation of this study was the fact that the HLA type of the women enrolled in this study was 













Limitations of this study 
Although there was a narrower response during acute infection, general statements of the regions 
and individual peptides targeted should be treated with caution because of the small number of 
samples and the lack of longitudinal samples. In addition, the ELISPOT assay is the most cost 
effective quantitative method for mapping epitope responses in HIV, this method generally 
allows only a single function to be measured at any time and IFNγ was measured in this study.  
While IFNγ has proven to be a useful surrogate for measuring CTL responses to HIV, other 
cytokines or T cell functions may be important in controlling HIV (Streeck et al., 2009) and 
polyfunctional T cell responses have been implicated in control (Betts et al., 2006).  In addition, 
the use of autologous virus sequence rather than consensus C peptides in this study may have 
enhanced the detection of HIV-specific T cell responses.  A previous study by Altfeld et al. 
(2003) showed that p24-specific T cell responses were slightly higher in magnitude (although not 
significantly) when peptides based on autologous virus sequences were used compared with 
consensus peptides.  Unlike flow cytometry and intracellular cytokine staining, the ELISPOT 
assay does not allow differentiation of the T cell subset responding to a particular peptide.  
ELISPOT approaches that detect two analytes have been developed that could overcome some of 
these limitation.  Alternatively, multi-colour flow cytometry could be used in future studies to 
simultaneously measure multiple functions of individual T cell subsets. 
 
Conclusions 
In conclusion, HIV Gag- and Nef-specific T cell responses were clearly detectable in the 
majority of acutely HIV-infected women included in this study.  In acutely infected women, 
HIV-specific responses were initially directed against a narrower array of peptides.  Both the 
number of peptides as well as the cumulative magnitude of responses to both Gag and Nef 
increased over time in each woman.  Throughout the first year of infection, responses to Gag and 
Nef were not conserved in women followed from acute infection but some peptide-specific 
responses were lost while others were gained, possibly reflecting loss of immunodominant 
responses to certain HIV epitopes because of CTL-induced immune escape in the circulating 













p24 region of Gag and specific peptides recognized over approximately 18 months of follow up 
were remarkably stable.  Few studies have investigated the evolution of T cell immune responses 
to HIV during subtype C infection and the role of responses mounted during acute infection in 
HIV subtype C pathogenesis.  Although this study focused on acute responses in only a small 
group of subtype C infected women living in Sub-Saharan Africa, the findings presented in this 
dissertation suggest that early HIV-specific responses following infection fluctuate over time 
with emergence of new immunodominant specificities possibly reflecting escape of the 
circulating virus from immune pressure.  In contrast, HIV-specific responses in LTNPs were 
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Establishment of quality control PBMCs reactive with CEF peptides to include 
on each plate and in each ELISPOT assay 
For quality assurance and in order to evaluate inter-assay and/or inter-plate variability 
in ELSIPOT, a single batch of PBMCs obtained from the Western Province Blood 
Transfusion Service was isolated and stored in ~10 identical aliquots in liquid 
nitrogen.  In order to establish this reference lot of PBMCs, 20 HIV negative white 
cell buffy packs were obtained and screened for responsiveness to CEF peptides from 
the Western Province Blood Transfusion Service.  White cell buffy packs are the 
cellular fraction of whole blood discarded by the Blood Transfusion Service after 
packed red blood cells have been removed.  From 1 donor buffy pack, ~108 viable 
PBMCs can be obtained and frozen down in liquid nitrogen in aliquots of 107 cells per 
vial for subsequent experiments.  PBMCs from these 20 uninfected donors were 
screened for responses to CEF peptides using the ELISPOT method described in 
Chapter 2 (section 2.12).  Two donors were identified as having the highest 
magnitude CEF-specific responses: WP5101 with a mean of 1447 SFU/106 cells and 
WP1425 with a mean of 549 SFU/106 cells. 
   
To determine the range of SFUs (including standard deviations) that would constitute 
a successful ELISPOT, replicates of 20 ELISPOT wells containing cells stimulated 
with CEF peptides from each of the selected donors were included in follow-up 
ELISPOT (shown in Figures A1 and A2).   
 
The mean SFUs (including standard deviations) were calculated from these 20 
replicates.  From the results shown in Figures A1 and A2, the range of SFUs 
acceptable for WP 5105 was 970 -1924 and for WP 1425 was 289 – 809 per 106 PBMC.  
For the detection of inter-assay variability in this study, the response to CEF peptides 
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Figure A1 PBMC from WP5101 stimulated with CEF peptides to establish SFU ranges 
for quality control.  The mean SFU and 3x Standard deviation was calculated to determine 






Figure A2 PBMC from WP1425 stimulated with CEF peptides to establish SFU ranges 
for quality control.  The mean SFU and 3x Standard deviation was calculated to determine 




In this study, PBMC from both donors were used as CEF controls.  PBMC and CEF 
were plated in triplicate as described in Chapter 2 section 2.12.  Eleven plates were 
used in the study which included control WP5105 (Figure A3 A) and 22 plates which 
included WP1425 as control (Figure A3 B).  10/11 (91%) assays for WP5105 were 
within the recommended range and one plate was slightly above the upper SFU range, 
although the result for that assay (plate 9) was accepted.  All the assays which 























































Figure A3 Range of inter assay CEF control obtained by ELISPOT.  The red line is the 
mean and the green lines are the standard deviations (upper and lower) as calculated. A: In 
this study, PBMC from donor WP5105 were included in eleven assays and each spot which 
matched the calculated SFU per 106 PBMC, was plotted and checked if the  range was 
maintained between (Figure A1) 970 -1924 SFU per 106 cells to monitor inter assay 
variability.  B: In this study, PBMC from donor WP1425 were included in 22 assays and each 
spot which matched the calculated SFU per 106 PBMC was plotted and checked if the range 


























Optimization of PHA concentration for ELISPOT 
PHA is a mitogen which reacts with and stimulates most mammalian cells. A 
comparative study was initially done to compare the ability of PHA (Sigma) to two 
different manufacturers to stimulate IFN-γ production in an ELISPOT assay.  PHA 
was purchased from Sigma (Sigma-Aldrich, USA), Fluka (Buchs Switzerland) and 
Remel (Remel Europe Ltd.).  PBMC from a HIV negative donor from Western 
Province Blood Transfusion Services (Pinelands, Cape Town) was stimulated with 
these three different PHAs at comparable concentrations; 16 and 24µg/ml (Sigma and 
Remel) and 20 and 40 µg/ml (Fluka).  PHA from Remel and Fluka were previously 
used in our laboratory at these concentrations; and it is known from our experience 
that PHA from Fluka yields a lower SFU than PHA (Remel). Therefore, an initial 
concentration for PHA (Sigma) was selected that was similar to Remel.  Results are 
shown in Figure B1.  PBMCs were plated at 50 µl/well at a concentration of 2 
x106/ml.  From these experiments, no significant differences were observed in 
SFU/106 PBMCs when PHAs from Sigma or Remel were used but responses obtained 
using PHA from Sigma were significantly higher than those obtained using Fluka (p = 
0.03; Figure B2).  The current PHA from Sigma was at the concentration which 
yielded the highest response (16 µg /ml) was used for all subsequent experiments as 
the positive control.  
 
 
Figure B1 Comparison of IFN-γ responses generated using increasing concentrations of 
PHA from Fluka, Remel and Sigma.  Row 1: Duplicates of PHA (Fluka; A= 20µg /ml 
B=40µg /ml).  Row2: Duplicates of PHA (Remel; A=16 µg /ml and B=24µg /ml).  Row 3: 
Duplicates of PHA (Sigma; A=16 µg /ml and B=24µg /ml).  Included in this assay were 


































Figure B2 Comparison of IFN-γ responses generated using increasing concentrations of 
PHA from Fluka, Remel and Sigma.  Each dot (Sigma, 16 µg /ml and 24µg /ml)), square 
(Remel, 16µg /ml and 24µg /ml) and triangle (Fluka, 20µg/ ml and 40µg /ml) represents 





Quality control between different batches of HIV Gag peptides by ELISPOT  
Two different batches of HIV Gag peptides were used in this study and a comparative 
ELISPOT was performed to compare the efficacy of each peptide batch to stimulate 
IFN-γ production by ELISPOT.  PBMCs from two HIV-1 positive donors were 
stimulated with the new Gag pools 1 - 5 prepared exclusively for this study and with 
the current Gag pools 1-5 routinely used in the laboratory.  Figure C1 shows the 
comparative response magnitudes obtained from 2 donors.  According to the results, 
IFN-γ responses that were generated using the new set of Gag pools significantly 
correlated to the responses produced by the existing Gag (p = 0.01, Spearman Rho = 





























Figure C1 Comparison of different batches of HIV Gag peptides to stimulate IFNγ 
responses by ELISPOT.  Row 1 represents PBMCs from Donor A and B with current Gag 
pools 1-5.  Row two represents PBMC from Donor A and B with the new set of Gag 1-5 
































Figure C2 Association between two different HIV Gag peptide pools.  Each dot represents 
matched measurement of IFN-γ  responses (SFU/106 PBMC) of current set and new set of 
HIV- Gag pools 1-5.  Mann-Whitney U tests were applied to compare these non-parametric 
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Kinetics of HIV plasma viral load and CD4 T cell counts during the course of 
HIV infection 
 
HIV RNA viral load (Tables A1 for acute infection and A3 for LTNPs) and CD4 T 
cell counts (Table A2 for acute infection and A4 for LTNPs) measurements of seven 
women acutely infected with HIV and nine LTNPs were monitored throughout the 
duration of this study.   
 
Table A1 Kinetics of plasma HIV viral load during the course of acute HIV infection 
 
PID Incident 
HIV viral loads (RNA copies/ml plasma) at each time point post infection (months) 
1 2 3 4 6 9 12 18 24 30 
C001  - 9430 4460 2020 6980 4890 4440 2430 4230 20200 18400 
C002 7480 - - 4510 7410 - - - - - - 
C004 11000 - - 87600 102000 14400 182000 87600 134000 42800 - 
C007 228000 195000 196000 599000 - - - - - - - 
C008 16900 13900 < 50 6550 15500 < 50 10500 41600 7820 - - 
B349 6400 - - - - - - - - - - 
B420 31200 - - - - - - - - - - 
Median 13950 13900 4460 6550 11455 4890 10500 41600 7820 31500 - 
Min 6400 9430 <50 2020 6980 <50 4440 2430 4230 20200 - 
Max 228000 195000 196000 599000 102000 14400 182000 87600 134000 42800 - 
 
 
Table A2 CD4 decline during the course of acute HIV infection 
PID Incident 
CD4 T cell counts at each time point post infection (months) 
1 2 3 4 6 9 12 18 24 30 
C001 548 747 708 759 555 543 550 615 651 579 521 
C002 548 - - 592 581 - - - - - - 
C004 867 - - 829 495 865 692 675 471 554 - 
C007 177 383 373 274 - - - - - - - 
C008 787 818 720 776 925 703 567 537 505 - - 
B349 305 - - - - - - - - - - 
B420 298 - - - - - - - - - - 
Mean 504 649 600 646 639 704 603 609 542 567 -  















Table A3 Kinetics of plasma HIV load during the course of LTNP infection. 
 
   Plasma HIV loads (RNA copies/ml) at each time point during chronic infection (months) 
PID 66 72 78 84 90 96 102 108 114 120 132 
NY010 <50 - <50 - <50 - - - - - - 
NY040 - - - 7200 3100 - - 32000 - - - 
NY064 - - - 930 2900 2400 1700 - - - - 
NY094 - 1700 1900 - 4400 - - - - - - 
NY099 - 10000 8500 - - 16000 - - - - - 
NY100 - - - - 53000 56000 - - - - - 
NY219 16000 20000 94 - - - - - - - - 
NY234 - 2 600 - - 17 000 - - - - - - 
NY292 - - - - - - - < 50 64 75 370 
Median 8025 6300 997 4065 3750 16000 - 16025 - - - 
Min <50 1700 <50 930 <50 2400 - <50 - - - 
Max 16000 20000 8500 7200 53000 56000 - 32000 - - - 
  
 
Table A4 Kinetics of CD4 counts during the course of LTNP HIV infection. 
    CD4 T cell counts (cell/µl) at each time point during chronic infection (months) 
PID 66 72 78 84 90 96 102 108 114 120 132 
NY010 334  - 422 - 521 - - - - - - 
NY040  -  - - 322 396 - - 300 - - - 
NY064  -  -  - 383 443 324 790 - - - - 
NY094  - 465 427 - 428 - - - - - - 
NY099 - 525 630 - - 383 - - - - - 
NY100  -  - - - 778 599 - - - - - 
NY219 551 465 265 - - - - - - - - 
NY234  - 680  - - 775 - - - - - - 
NY292  - -   - - - - - 529 536 574 605 
Mean 443 534 436 353 557 435 - 415 - - - 
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